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on a snapshot day in 2013, over 47,000 clients 
received pharmacotherapy treatment for their opioid 
dependence at 2,355 dosing points around australia.
as in previous years, methadone was the most common 
pharmacotherapy drug, with around two-thirds (68%) 
of clients treated with this drug. there were 2,025 
prescribers of opioid pharmacotherapy drugs, an 
increase of 15% from 2012.
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Summary 
Dependence on opioid drugs such as heroin and morphine is associated with a range of 
health and social problems. Treatment with an opioid pharmacotherapy drug can reduce 
drug cravings, improve physical and mental health and reduce drug-related crime. 
Over 47,000 Australians received pharmacotherapy treatment for their opioid dependence 
on a snapshot day in June 2013. 
The number of people receiving opioid pharmacotherapy treatment (clients) almost doubled 
between 1998 (from around 25,000) and 2013, but growth in client numbers slowed in recent 
years (to less than 1% a year from 2010–2013). 
Methadone continues to be the drug most commonly prescribed and the form in which 
buprenorphine is prescribed is changing. 
Around two-thirds (68%) of clients received methadone in 2013, with the proportion 
remaining relatively stable since 2006. The remaining third (32%) received 1 of 2 forms of 
buprenorphine. Of these, the proportion receiving buprenorphine only has fallen (from 23% 
to 13%) while the proportion receiving buprenorphine combined with naloxone has risen 
(from 6% to 20%) over the same period. Naloxone is added to buprenorphine to deter 
injection of the medication. 
Opioid pharmacotherapy clients are getting older on average.  
In 2013, around two-thirds (69%) of clients were aged 30–49, and this proportion has been 
fairly consistent since 2006. However, from 2006–2013 the proportion of clients aged less 
than 30 more than halved (from 28% to 11%), and the proportion of clients aged 50 and over 
more than doubled (from 8% to 19%). These trends suggest an ageing population of clients in 
pharmacotherapy treatment. 
Males and Aboriginal and Torres Strait Islander people are over-represented in 
pharmacotherapy treatment.  
Around two-thirds (65%) of clients receiving pharmacotherapy in June 2013 were male. 
Where reported, almost 1 in 10 (9%) clients identified as Indigenous. Indigenous people were 
around 3 times as likely to have received pharmacotherapy treatment as other Australians. 
Prescriber numbers have increased, and most work in the private sector.  
There were 2,025 prescribers of opioid pharmacotherapy in Australia in 2013, an increase of 
15% from 2012. On average, each prescriber treated fewer clients, with the ratio of clients per 
prescriber falling from 26 in 2012 to 23 in 2013. The majority of prescribers worked in the 
private sector (82%) and were authorised to prescribe more than 1 type of pharmacotherapy 
drug (71%). 
Most dosing points were located in pharmacies.  
Most clients need to attend a dosing point regularly to take their opioid pharmacotherapy 
drug under supervision. In 2012–13 there were 2,355 dosing point sites in Australia, and 9 in 
10  (88%) of these were located in pharmacies.  
Heroin is the most common opioid drug leading people to pharmacotherapy treatment. 
Clients were about twice as likely to report heroin as an opioid drug of dependence than 
they were for all opioid pharmaceuticals combined; however this varied by jurisdiction. 
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1 Introduction 
Dependence on opioid drugs such as heroin and morphine is associated with a range of 
health and social problems that affect individual drug users, their family and friends, and the 
wider public, and is considered a serious public health issue (WHO 2013; see also Box 1.1). In 
2010, about 3% of Australians used opioids for non-medical reasons, while 1.4% had used 
heroin over their lifetime (AIHW 2011). Among those Australians seeking treatment for drug 
and alcohol problems in 2011–12, opioids were a drug of concern in about 1 in 8 (13%) 
treatment episodes (AIHW 2013a).  
Box 1.1: What is opioid drug dependence? 
Drug dependence is a condition characterised by patterns of thought and behaviour that 
relate to drug seeking and using, and may be expressed differently from person to person. 
There are a range of different tools used to define and diagnose drug dependence including 
opioid dependence. The International Statistical Classification of Diseases and Health 
Related Problems (ICD-10) (WHO 2010) defines ‘dependence syndrome’ due to the use of 
opioids as: 
‘A cluster of behavioural, cognitive, and physiological phenomena that develop after 
repeated substance use and that typically include a strong desire to take the drug, 
difficulties in controlling its use, persisting in its use despite harmful consequences, a higher 
priority given to drug use than to other activities and obligations, increased tolerance, and 
sometimes a physical withdrawal state (Code F11.2).’ 
1.1 What are opioid drugs? 
Opioid drugs include: 
• illicit opioids, predominantly heroin (WHO 2013) 
• prescription opioids (whether prescribed for the person or obtained illicitly) such as 
morphine and oxycodone (Roxburgh et al. 2011) 
• over-the-counter opioids in which the opioid drug codeine is combined with a 
non-opioid analgesic such as paracetamol or ibuprofen (Nielsen et al. 2010). 
Opioid drugs depress the central nervous system and are widely used to treat pain due to 
their analgesic effect. Other effects include sedation and euphoria, and repeated use of 
opioids can lead to drug dependence—a chronic, relapsing condition (NSW Health 2006). 
1.2 What problems can opioid dependence cause? 
Problems associated with heroin dependence include: 
• overdose deaths 
• the spread of diseases such as HIV and Hepatitis B and C due to needle sharing 
• medical and psychological complications 
• social and family disruption 
• harm to the welfare of children 
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• violence and drug-related crime (NSW Health 2006). 
Overdose, injection-related harm and other harms due to dependence are also related to the 
non-medical use of prescription opioids (Roxburgh et al. 2011). Dependence on  
over-the-counter opioids can also lead to life-threatening paracetamol or ibuprofen overdose 
due to the large number of tablets taken to achieve the required codeine dose (Nielsen et al. 
2010). 
1.3 What treatment is available? 
Opioid dependence is a condition that requires long-term treatment. Treatment is tailored to 
the person’s individual circumstances, and treatment types may be combined (for example, 
opioid pharmacotherapy combined with counselling) or varied over time (NDARC 2004). 
The 3 main treatment approaches for opioid dependence are: 
• detoxification (also called withdrawal) 
• opioid pharmacotherapy (also called substitution or maintenance treatment) 
• abstinence-based treatments: 
– self-help groups 
– counselling 
– therapeutic communities (NDARC 2004). 
The broad goal of treatment for opioid dependence is to reduce the health, social and 
economic harms to individuals and the public arising from dependence (DoHA 2007). 
Pharmacotherapy treatment 
Opioid pharmacotherapy involves replacing the drug of dependence with a legally obtained, 
longer-lasting opioid that is taken orally. It reduces or eliminates withdrawal symptoms and 
drug cravings (NDARC 2004). Research suggests that pharmacotherapy treatment reduces 
heroin use, other opioid substance misuse and associated criminal behaviour, and improves 
physical and mental health, and social functioning (Ritter & Chalmers 2009). 
In Australia, 3 medications are registered for long-term maintenance treatment for  
opioid-dependent people (see Box 1.2): 
• methadone oral liquid (available since 1969) 
• buprenorphine tablet (available since 2000) 
• buprenorphine-naloxone tablet (available since 2005) or film (available since 2011) 
(DoHA 2007; DoHA 2012). 
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Box 1.2: Pharmacotherapy types in the NOPSAD collection 
The National Opioid Pharmacotherapy Statistics Annual Data (NOPSAD) collection on 
which this report is based includes data on the 3 pharmacotherapy drugs described below.  
Methadone (Methadone Syrup®, Biodone Forte®) 
Methadone is a synthetic opioid used to treat heroin and other opioid dependence. It 
reduces opioid withdrawal symptoms, the desire to take opioids and the euphoric effect 
when opioids are used. It is taken orally on a daily basis (DoHA 2007). 
Buprenorphine (Subutex®) 
Buprenorphine acts in a similar way to methadone, but is longer-lasting and may be taken 
daily or every second or third day. Two buprenorphine preparations are registered in 
Australia for the treatment of opioid dependence: a product containing buprenorphine only 
and a combined product containing buprenorphine and naloxone. The buprenorphine-only 
product is available as a tablet containing buprenorphine hydrochloride that is 
administered sublingually (by dissolving under the tongue) (DoHA 2007). 
Buprenorphine-naloxone (Suboxone®) 
The combination buprenorphine-naloxone product is a sublingual tablet or film containing 
buprenorphine hydrochloride and naloxone hydrochloride (DoHA 2012). It is 
recommended that buprenorphine-naloxone should be prescribed in preference to 
buprenorphine for most clients receiving takeaway doses (DoHA 2007). This is because, 
when taken as intended by dissolving the tablet or film under the tongue, the combined 
product acts as if it was buprenorphine alone. However, if the combined product is injected, 
naloxone can block the effects of buprenorphine and increases opioid withdrawal 
symptoms. This reduces the risk that those receiving buprenorphine-naloxone as a 
takeaway dose will inject it or sell it to others to inject (Chapleo & Walter 1997; DoHA 2007; 
Dunlop 2007). 
1.4 How is opioid pharmacotherapy provided in 
Australia? 
The current Australian opioid pharmacotherapy system seeks to strike a balance between 
maximising accessibility of treatment and minimising the risks associated with 
non-compliance (injecting medication) and diversion (selling or swapping medication) 
(Ritter & Chalmers 2009). Methadone and buprenorphine are Schedule 8 (controlled) drugs, 
which means there are strict regulations associated with their use (Ritter & Chalmers 2009). 
Clients seek or are referred to treatment for their opioid dependence. A health professional 
who is authorised to provide opioid pharmacotherapy (a prescriber) prescribes methadone, 
buprenorphine or buprenorphine-naloxone as part of the client’s treatment plan. Clients are 
not usually given a whole course of their medication for use at home. Rather, the client 
attends a dosing point regularly and takes 1 dose of their prescribed medication under the 
supervision of a pharmacist or other health professional. Some takeaway doses may be given 
to eligible clients. See Box 1.3 for more information. 
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Responsibilities and costs 
The Australian and state and territory governments share responsibility and costs for the 
provision of opioid pharmacotherapy services. Depending on where pharmacotherapy is 
dosed, clients may be charged a dispensing fee. 
As described by Ritter and Chalmers (2009), the Australian Government: 
• sets the national policy for opioid pharmacotherapy (DoHA 2007; new policy due for 
release shortly) 
• provides national clinical practice guidelines for methadone and buprenorphine  
• provides methadone and buprenorphine free of charge to the dosing body under the 
Pharmaceutical Benefits Scheme (PBS) 
• funds private-sector prescribing (for example, by general practitioners) through 
Medicare. 
State and territory governments: 
• administer the delivery of opioid pharmacotherapy 
• set policies and clinical guidelines for their jurisdiction 
• regulate, train and accredit prescribers and dosing points 
• register and monitor clients 
• fund prescribing and dosing in public clinics and prisons 
• subsidise service providers in some instances. 
Depending on the state or territory and the dosing point type (Box 1.3), opioid 
pharmacotherapy for clients can be either free or charged. Under the provisions of the PBS 
for the Opiate Dependence Treatment Program, the drugs are provided free to dosing points. 
Clients may be charged a dispensing fee when receiving medication. This cost may limit 
clients’ access to opioid pharmacotherapy (Ritter & Chalmers 2009). In most cases, dosing at 
public clinics is free, at least for a limited time (see Chapter 5 for more information). 
Prescribers 
Each state and territory has rules about how prescribers are authorised to prescribe 
methadone, buprenorphine and buprenorphine-naloxone. Each runs professional training 
programs for medical personnel wishing to be approved as prescribers (DoHA 2007). In 
some states and territories, doctors can be authorised to prescribe to up to 5 ongoing clients 
without attending a training course, if these clients have first been seen by a medical 
practitioner with accredited training (ACT Health 2009; NSW Health 2006). In South 
Australia and Victoria, medical practitioners can treat up to 5 new or ongoing clients with 
buprenorphine-naloxone film without undertaking training or without the client first seeing 
an accredited medical practitioner (SA Health 2011; Vic Health 2013). 
Being authorised or registered to prescribe pharmacotherapy for opioid dependence does 
not necessarily mean that the prescriber will prescribe this medication during any given 
year. Prescribers who have prescribed pharmacotherapy for a client with opioid dependence 
in a given financial year are referred to as ‘active prescribers’ (Box 1.3). 
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Dosing 
At the start of treatment, clients need to attend the clinic or pharmacy to take their dose 
under supervision. However, the requirement to travel regularly to the dosing point can be a 
barrier to both ongoing participation in treatment and social reintegration. To overcome 
these issues, there is a provision for takeaway doses for stable clients in some circumstances 
(DoHA 2007). Policies on takeaway dosing vary by state or territory. For more information, 
refer to the individual state and territory policies and guidelines for treating opioid 
dependence in Table 5.3. Where takeaway dosing is allowed, it is preferred that clients on 
buprenorphine are given the combination buprenorphine-naloxone product (DoHA 2007). 
1.5 What information is included in the NOPSAD 
collection? 
The NOPSAD collection commenced in 2005 and comprises data about opioid 
pharmacotherapy clients, prescribers and dosing points collected by state and territory 
health departments and reported to the AIHW (see Box 1.3 for further information). Prior to 
2005, information was provided each year to the Australian Government Department of 
Health. 
Box 1.3: Definitions for the NOPSAD collection 
Several terms used throughout this report are specific to the NOPSAD collection and its 
subject matter. Full definitions are in the NOPSAD 2013 collection data guide (see 
<https://www.aihw.gov.au/nopsad/>), which is made available each year to complement 
the NOPSAD report and provide a clearer understanding about what is and what is not 
being reported. 
Specified/snapshot day or snapshot day is a particular day, usually in June each year, on 
which clients are counted for the NOPSAD collection. The snapshot day varies between 
states and territories, but allows the number of clients to be estimated at a single point in 
time. See Chapter 5 for information about the use of the snapshot day for each state and 
territory. 
Client refers to a person registered as receiving opioid pharmacotherapy treatment on the 
snapshot day. 
Prescriber refers to a registered prescriber who is accredited and/or authorised to prescribe 
a pharmacotherapy drug and who has not been recorded as ceasing this registration before 
the snapshot day. More specifically, prescribers are included in the count if they are 
registered or active prescribers, that is, prescribers who are scripting at least 1 client during 
the reporting period (that is, each financial year). 
Prescriber type is defined as the sector (public or private) in which the prescriber is 
practising when prescribing pharmacotherapy drugs. 
Dosing point site refers to a place at which at least 1 client is provided a pharmacotherapy 
drug on the snapshot day. Sites include public and private clinics (such as methadone 
clinics), pharmacies, correctional facilities, hospitals (admitted patients and outpatients) and 
other locations such as community health centres and doctors’ surgeries. 
While states and territories strive to report data consistent with agreed standards, the 
NOPSAD collection is not a national minimum data set and some discrepancies exist in the 
way data are reported. For example, reporting systems in New South Wales do not 
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distinguish between buprenorphine and buprenorphine-naloxone. As such, New South 
Wales data relating to both these products are reported under the category of 
buprenorphine. Such discrepancies are discussed in more detail in Chapter 5. 
1.6 What is new in the 2013 NOPSAD collection? 
The 2013 NOPSAD collection included 2 new data items. These sought information on: 
• the opioid drug(s) leading clients to pharmacotherapy treatment  
• whether pharmacotherapy clients were continuing, new, readmitting or transferring 
from interstate on a snapshot day.  
Analyses based on these new data items are provided in Section 2.4. Due to the incomplete 
reporting of these data, however, the results should be interpreted carefully. 
While the 2012 NOPSAD collection was the first to include state and territory unit record 
data (in addition to aggregated tables) provided to the AIHW, variable data quality 
prevented these being reported. In 2013, data quality improvements have allowed for de-
identified aggregate output based on unit record analyses to be included for the first time. 
Six states and territories provided unit record data: New South Wales, Western Australia, 
South Australia, Tasmania, the Australian Capital Territory and the Northern Territory. For 
a number of these jurisdictions, some data items were reported incompletely or not reported. 
For this reason, analyses based on 2013 unit record data should be interpreted with caution. 
This transition from reporting aggregate level to unit record level information will allow for 
more nuanced data analysis to be conducted, which will lead to improved, policy relevant 
reporting in future. 
States and territories implement policy, administrative and methodological changes that can 
affect the NOPSAD collection. In 2013, 2 material changes relating to Victoria occurred. First, 
general practitioners can now prescribe buprenorphine-naloxone to a small number of clients 
(up to 5) without attending specific training. This policy change is similar to that which 
occurred in South Australia in 2011 and has contributed toward an increase in the number of 
prescribers. Second, due to changes in data reporting, information on the age and sex of 
clients for each pharmacotherapy drug type in 2013 was not provided for Victoria. Full 
details on policy, administrative and methodological arrangements for all states and 
territories can be found in Chapter 5. 
1.7 What is the NOPSAD collection used for? 
Information about specialist drug and alcohol treatment services and their clients is collected 
by Australian, state and territory governments and compiled by the Australian Institute of 
Health and Welfare (AIHW) to form the Alcohol and Other Drug Treatment Services 
National Minimum Data Set (AODTS NMDS) (AIHW 2013a). However, the treatment 
settings for opioid pharmacotherapy—including correctional facilities and private clinics, as 
well as the role of pharmacists and general practitioners in delivering opioid 
pharmacotherapy—are very diverse. This places this area generally out of scope for the 
AODTS NMDS. 
The NOPSAD collection is one of a number of data sources that provide a picture of alcohol 
and other drug treatment services in Australia. Data from the collection can be considered 
with information from other sources (for instance, the AODTS NMDS, the National Drug 
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Strategy Household Survey and the Health of Australia’s Prisoners reports – see Appendix 
C) to inform public debate, policy decisions and planning processes that occur within the 
broader alcohol and other drug treatment sector. More specifically, pharmacotherapy data 
are used by state and territory governments to: 
• monitor resources required for pharmacotherapy treatment, such as the number of 
prescribers and dosing point sites 
• monitor and plan services (for example, monitoring prescriber patterns and the number 
of clients) 
• develop and refine policies relating to the treatment of clients with opioid dependency 
• track the number of clients moving between the public and private sectors. 
Data are also used to fill gaps in national treatment services data. See appendixes A, B and C 
for more information about the NOPSAD data as well as related data collections. 
The NOPSAD reports are available free online at <www.aihw.gov.au/alcohol-and-other-
drugs/>. 
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2 Clients 
2.1 How many people receive opioid 
pharmacotherapy treatment? 
On a snapshot day in June 2013, 47,442 clients were receiving opioid pharmacotherapy 
treatment in Australia, an increase of 745 from 2012. Client numbers grew slightly (by less 
than 1% annually) between 2010 and 2013 (Figure 2.1). In contrast, between 1998 and 2004, 
and again between 2007 and 2010, client numbers grew by 5–13% a year.  
 
 
Source: Table A1. 
Figure 2.1: Clients receiving pharmacotherapy on a snapshot day, 1998–2013 
 
Nationally, the number of clients per 10,000 people increased from 13 in 1998 to 21 in 2010, 
but has since remained stable at 21 (Table A1). In 2013, New South Wales had the highest 
rate of clients (26 clients per 10,000 population), followed by Victoria (24) and the Australian 
Capital Territory (24). The Northern Territory had the lowest rate of clients (6 clients per 
10,000 population) (Figure 2.2). The low rate of clients in the Northern Territory may be 
partially attributable to the absence of an established heroin market in Darwin (Moon 2010), 
the impact of remote locations on treatment delivery, and a highly mobile population. Rates 
for all states and territories varied only slightly over the last 3 collection years. 
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Source: Table A2. 
Figure 2.2: Rate of clients receiving pharmacotherapy on a snapshot day, by state and territory, 
2011–2013 
2.2 What drugs do clients receive? 
On a snapshot day in June 2013: 
• 67% of clients received methadone 
• 13% received buprenorphine 
• 20% received buprenorphine-naloxone (Table A3). 
However, it should be noted that New South Wales does not report clients receiving 
buprenorphine-naloxone separately, but rather includes them within the total number of 
clients receiving buprenorphine. If New South Wales data are excluded, in the rest of 
Australia: 
• 62% of clients received methadone 
• 5% received buprenorphine 
• 33% received buprenorphine-naloxone. 
From 2008–2013, the national proportion of clients receiving methadone fell slightly from 
70% to 67% (Figure 2.3). In the same period, the proportion of clients receiving 
buprenorphine fell from 15% to 13%, while the proportion receiving 
buprenorphine-naloxone rose from 16% to 20%. Data prior to 2008 should be interpreted 
with caution, as separate data collection for buprenorphine-naloxone did not start until 2007 
or 2008 in some jurisdictions (see Chapter 5 for more details). Separate data collection for 
buprenorphine and buprenorphine-naloxone has not yet commenced in New South Wales. 
Nonetheless, it appears that buprenorphine-naloxone prescription is replacing 
buprenorphine prescription to some extent. This is in keeping with national guidelines 
(DoHA 2007), which recommend that buprenorphine-naloxone should be preferred over 
buprenorphine for most clients receiving takeaway doses.  
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Notes 
1. Data collection for buprenorphine-naloxone started at different times: 2006 for Vic, WA, SA, NT; 2007 for Tas and the ACT; and 2008 for 
Qld. 
2. NSW counts buprenorphine-naloxone as ‘buprenorphine’. See Chapter 5 for further details. 
Source: Table A3.  
Figure 2.3: Clients receiving pharmacotherapy on a snapshot day, by pharmacotherapy type,  
2006–2013 
 
The proportion of clients receiving each of the 3 pharmacotherapies varies across states and 
territories (Figure 2.4). In 2013, methadone was the most common pharmacotherapy in all 
jurisdictions except for the Northern Territory. The jurisdiction with the highest proportion 
of clients receiving methadone was the Australian Capital Territory (79%), followed by New 
South Wales (76%). In contrast, only 31% of clients in the Northern Territory were prescribed 
methadone. The Northern Territory had the highest proportion of clients receiving 
buprenorphine-naloxone (57%). Buprenorphine-naloxone is the default treatment drug for 
the main pharmacotherapy program in the Northern Territory. 
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Note: NSW counts buprenorphine-naloxone as 'buprenorphine'. See Chapter 5 for further details. 
Source: Table A3. 
Figure 2.4: Clients receiving pharmacotherapy on a snapshot day, by pharmacotherapy type and 
state and territory, 2013 
2.3 Who receives pharmacotherapy treatment? 
Age and sex 
Since 2006, when information about the age of a client was first collected, the proportion of 
older clients within the treatment population has increased. Around two-thirds (69%) of 
clients in 2013 were aged 30–49, and this proportion has been fairly consistent since 2006 
(Figure 2.5). However, from 2006–2013 the proportion of clients aged less than 30 more than 
halved (from 28% to 11%), and the proportion of clients aged 50 and over more than doubled 
(from 8% to 19%). This trend suggests an ageing cohort of people receiving opioid 
pharmacotherapy treatment. This trend toward older pharmacotherapy clients has also been 
observed overseas (see, for example, Doukas 2011 and Dürsteler-MacFarland et al. 2011) and 
may be due to: 
• methadone treatment having been available for more than 40 years 
• pharmacotherapy treatment reducing the risk of premature death, resulting in some 
clients remaining in treatment for decades 
• clients seeking treatment for the first time at an older age. 
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Source: Table A4. 
Figure 2.5: Clients receiving pharmacotherapy on a snapshot day, by age group, 2006–2013 
 
In 2013, clients ranged in age from their mid-teens to their late-80s. The median age of clients 
across all pharmacotherapy types was 40 years, compared with 39 in 2012 and 38 in 2011 (the 
first year these data were reported). At a state and territory level, clients in Victoria and 
Tasmania had the youngest median age (37 and 38 years respectively) and clients in New 
South Wales and South Australia had the oldest median age (41 years). 
Table 2.1: Median age of clients receiving pharmacotherapy on a snapshot day, by state and 
pharmacotherapy type, 2013 
  NSW Vic(a) Qld WA SA Tas ACT NT Australia(b) 
 Age (years) 
Methadone 42 n.a. 42 40 43 40 39 39 42 
Buprenorphine(c)  . . n.a. 38 35 40 36 40 37 . . 
Buprenorphine-naloxone n.a n.a. 38 38 39 35 39 39 . . 
Total 41 37 40 39 41 38 39 39 40 
(a) Vic data were not available for age by pharmacotherapy type. 
(b) The national median age for buprenorphine and buprenorphine-naloxone clients is not published due to lack of data coverage. 
(c) Due to NSW counting buprenorphine and buprenorphine-naloxone as ‘Buprenorphine’, the median age of NSW buprenorphine clients is not 
published. See Chapter 5 for further details. 
In 2013, methadone was the most commonly dispensed pharmacotherapy across all age 
groups (Figure 2.6). For older clients, the proportion receiving methadone was higher than 
for younger clients. Conversely, younger clients were more likely to receive buprenorphine 
or buprenorphine-naloxone than older clients. As buprenorphine was registered in Australia 
for opioid pharmacotherapy in 2000, and buprenorphine-naloxone was only registered in 
2005 (DoHA 2007), a possible explanation for the observed trend might be that some older, 
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long-term clients first entered treatment when methadone was the only available 
pharmacotherapy for opioid dependence. 
 
  
Notes  
1. Vic data were not available for age by pharmacotherapy type. 
2. NSW counts buprenorphine-naloxone as ‘buprenorphine’. As a result, the proportion of clients receiving buprenorphine-naloxone nationally 
is likely to be higher than reported in this figure. See Chapter 5 for further details. 
Source: Table A4. 
Figure 2.6: Clients receiving pharmacotherapy on a snapshot day, by age group and 
pharmacotherapy type, 2013 
 
Around two-thirds (65%) of all clients receiving pharmacotherapy on a snapshot day in June 
2013 were male (Table 2.2). This proportion has remained relatively stable since 2006 
(Table A5). Excluding Victoria, 63% of clients receiving methadone were male, as were 66% 
of clients receiving buprenorphine and buprenorphine-naloxone (Figure 2.7). 
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Note: Vic data were not available for sex by pharmacotherapy type. 
Source: Table 2.2. 
Figure 2.7: Clients receiving pharmacotherapy on a snapshot day, by sex and pharmacotherapy 
type, 2013 
Around two-thirds of clients were male in each state and territory, ranging from 59% in 
Tasmania to 66% in New South Wales and Victoria (Table 2.2).  
Table 2.2: Clients receiving pharmacotherapy on a snapshot day, by sex, 
pharmacotherapy type, and state and territory, 2013 
Sex NSW Vic(a) Qld WA SA Tas ACT NT Total Total (%) 
 
Methadone 
Male 9,491 n.a. 1,740 1,326 1,159 217 451 29 14,413 63.3 
Female 5,065 n.a. 1,312 801 710 158 278 16 8,340 36.6 
Not stated — n.a. 4 — — — — — 4 0.0 
Total 14,556 n.a. 3,056 2,127 1,869 375 729 45 22,757 100.0 
 
Buprenorphine(b) 
Male 3,146 n.a. 410 42 42 25 24 8 3,697 65.6 
Female 1,495 n.a. 298 65 36 30 6 10 1,940 34.4 
Not stated — n.a. — — — — — — — 0.0 
Total 4,641 n.a. 708 107 78 55 30 18 5,637 100.0 
 
Buprenorphine-naloxone 
Male n.a. n.a. 1,526 668 851 149 113 53 3,360 66.1 
Female n.a. n.a. 745 384 381 80 48 31 1,669 32.8 
Not stated n.a. n.a. 58 — — — — — 58 1.1 
Total n.a. n.a. 2,329 1,052 1,232 229 161 84 5,087 100.0 
 
Total (all pharmacotherapy drugs) 
Male 12,637 9,241 3,676 2,036 2,052 391 588 90 30,711 64.7 
Female 6,560 4,654 2,355 1,250 1,127 268 332 57 16,603 35.0 
Not stated —  66 62 — — — — — 128 0.3 
Total 19,197 13,961 6,093 3,286 3,179 659 920 147 47,442 100.0 
(a) Vic data were not available for sex by pharmacotherapy type. 
(b) NSW counts buprenorphine-naloxone as ‘buprenorphine’. See Chapter 5 for further details. 
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Compared to the general population, the proportion of people receiving pharmacotherapy 
was highest between ages spanning early 30s to mid-50s for both males and females (Figure 
2.8). The rate of pharmacotherapy clients peaked at the age of 36 for males and 35 for females 
(with 82 clients for every 10,000 males aged 36, and 46 clients for every 10,000 females aged 
35). Males were generally more likely—and in some cases about twice as likely—to be 
receiving pharmacotherapy when compared to females of the same age. 
 
  
Notes 
1. Unit record data were used to produce this figure. Records were available for 58% of total clients receiving pharmacotherapy on a 
snapshot day in 2013. Vic and Qld data were not available. 
2. Australian population estimates for June 2013 were used to produce this figure (ABS 2014a). 
Source: Table A6. 
Figure 2.8: Clients receiving pharmacotherapy on a snapshot day, by age and sex, 2013 
 
While the age profiles of male and female pharmacotherapy clients were similar in 2013, 
females tended to be slightly younger and males slightly older (Figure 2.9). From the ages of 
20–34, the proportion of female clients exceeded males for each 5-year age group; the 
proportion of male clients exceeded females for almost all groups aged 35 and over. 
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Note: Unit record data were used to produce this figure. Records were available for 58% of total clients receiving pharmacotherapy on a snapshot 
day in 2013. Vic and Qld data were not available. 
Source: Table A7. 
Figure 2.9: Clients receiving pharmacotherapy on a snapshot day, by age group and sex, 2013 
Aboriginal and Torres Strait Islander people 
In 2013, 6 states and territories were able to provide information about the Indigenous status 
of clients receiving pharmacotherapy treatment. Victoria and Western Australia did not 
report the Indigenous status of their clients, with the result that Indigenous status was only 
reported for around two-thirds (64%) of clients in the collection. Furthermore, Indigenous 
status was not stated for 9% of clients in the 6 reporting states and territories. Jurisdictions 
are working toward improving the quality of Indigenous data for this collection. The 
analysis of the 2013 data that follows should be treated with caution due to the high 
proportion of clients (42%) for whom Indigenous status is either not reported or not stated. 
Of the 30,195 clients in the 6 jurisdictions reporting Indigenous status in 2013, 2,822 (9%) 
identified as being of Aboriginal and/or Torres Strait Islander origin (Table 2.3). The 
proportion of clients who were Indigenous ranged from 4% in Queensland to 11% in New 
South Wales and the Northern Territory. 
Overall, for the 6 states and territories reporting Indigenous status, there were 59 Indigenous 
clients per 10,000 Indigenous people. When compared to the rate for non-Indigenous clients 
(17 clients per 10,000 non-Indigenous people), this suggests an over-representation of 
Indigenous people receiving pharmacotherapy treatment. Three jurisdictions had relatively 
high rates of Indigenous clients: the Australian Capital Territory (188 clients per 10,000 
Indigenous people), New South Wales (122) and South Australia (83). The high rate in the 
Australian Capital Territory should be regarded with caution as it has a small Indigenous 
population. In contrast, Queensland had 15 Indigenous clients per 10,000 Indigenous people, 
Tasmania had 14 and the Northern Territory just 2 Indigenous clients per 10,000 Indigenous 
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people. This low rate in the Northern Territory is consistent with the low overall rate of 
pharmacotherapy (6 clients per 10,000 people). 
Three-quarters (73%) of Indigenous clients received methadone, with the remaining quarter 
(27%) receiving either buprenorphine or buprenorphine-naloxone (Table 2.3).  
Table 2.3: Clients receiving pharmacotherapy on a snapshot day, by Indigenous status, 
pharmacotherapy type, and state and territory, 2013 
Indigenous status NSW Vic Qld WA SA Tas ACT NT Total Total (%) 
 Methadone 
Indigenous 1,679 n.a. 131 n.a. 152 21 85 5 2,073 10 
Non-Indigenous 11,017 n.a. 2,512 n.a. 1,717 299 632 40 16,217 79 
Not stated 1,860 n.a. 413 n.a. — 55 12 — 2,340 11 
Sub total 14,556 n.a. 3,056 n.a. 1,869 375 729 45 20,630 100 
Not reported(a) — 9,234 — 2,127 — — — — 11,361 n.a. 
Total 14,556 9,234 3,056 2,127 1,869 375 729 45 31,991 . . 
 
Buprenorphine(b) 
Indigenous 468 n.a. 33 n.a. 4 2 — 3 510 9 
Non-Indigenous 3,979 n.a. 656 n.a. 74 47 29 14 4,799 87 
Not stated 194 n.a. 19 n.a. — 6 1 1 221 4 
Sub total 4,641 n.a. 708 n.a. 78 55 30 18 5,530 100 
Not reported(a) — 531 — 107 — — — — 638 n.a. 
Total 4,641 531 708 107 78 55 30 18 6,168 . . 
 
Buprenorphine-naloxone 
Indigenous n.a. n.a. 102 n.a. 112 7 10 8 239 6 
Non-Indigenous n.a. n.a. 2,091 n.a. 1,120 191 148 75 3,625 90 
Not stated n.a. n.a. 136 n.a. — 31 3 1 171 4 
Sub total n.a. n.a. 2,329 n.a. 1,232 229 161 84 4,035 100 
Not reported(a) n.a. 4,196 — 1,052 — — — — 5,248 n.a. 
Total n.a. 4,196 2,329 1,052 1,232 229 161 84 9,283 . . 
 
Total (all pharmacotherapy drugs) 
Indigenous 2,147 n.a. 266 n.a. 268 30 95 16 2,822 9 
Non-Indigenous 14,996 n.a. 5,259 n.a. 2,911 537 809 129 24,641 82 
Not stated 2,054 n.a. 568 n.a. — 92 16 2 2,732 9 
Sub total 19,197 n.a. 6,093 n.a. 3,179 659 920 147 30,195 100 
Not reported(a) — 13,961 — 3,286 — — — — 17,247 n.a. 
Total 19,197 13,961 6,093 3,286 3,179 659 920 147 47,442 . . 
  Number of Indigenous clients per 10,000 Indigenous people(c) 
  122 n.a. 15 n.a. 83 14 188 2 59   
 Number of Non-Indigenous clients per 10,000 non-Indigenous people(c) 
 21 n.a. 11 n.a. 18 11 23 8 17  
(a) Vic and WA do not report Indigenous status. 
(b) NSW counts buprenorphine-naloxone as ‘buprenorphine’. See Chapter 5 for further details. 
(c) Population estimates for Indigenous and Non-Indigenous people are for June 2013 (ABS 2014b) 
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In 2013, 5 states and territories provided confidentialised client data (unit records) including 
Indigenous status information. The following aggregated information is based on those data 
and, as with the data reported above, should be interpreted with caution due to the high 
proportion of individual clients (54%) for whom Indigenous status is either ‘not reported’ or 
‘not stated’. 
Drawing on this richer data for 5 states and territories, Indigenous pharmacotherapy clients 
tended to be younger than pharmacotherapy clients in general (Figure 2.10). For age groups 
under 45 years, Indigenous clients were over-represented compared to pharmacotherapy 
clients as a whole. For each older age group, the proportion of Indigenous pharmacotherapy 
clients was lower than that seen for pharmacotherapy clients generally, by as much as 
two-thirds for some age groups. 
 
Note: The figure includes unit record data from NSW, SA, Tas, the ACT and the NT. Qld data were not available; Vic and WA do not report 
Indigenous status. 
Source: Table A8. 
Figure 2.10: Clients receiving pharmacotherapy on a snapshot day, by Indigenous status and age 
group, 2013 
2.4 Opioid drug of dependence and client status 
The 2013 NOPSAD collection included 2 new types of information on pharmacotherapy 
clients. These relate to clients’ opioid drugs of dependence (the drugs leading people to seek 
opioid pharmacotherapy treatment) and their status (the numbers of new, ongoing or 
readmitting clients, and clients transferring from another state/territory jurisdiction). 
Because the data items are new to the collection, a high rate of ‘not stated’ and ‘not reported’ 
responses were received in this first year. The following information should therefore be 
interpreted with caution.  
Which drugs do clients receive treatment for? 
Opioid pharmacotherapy clients receive treatment for a range of drugs of dependence. These 
include illicit opioids (such as heroin) and pharmaceutical opioids, which are available 
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illicitly, by prescription (such as morphine and oxycodone) or over-the-counter (such as 
codeine–paracetamol combinations). 
At the national level, clients were about twice as likely to report heroin as an opioid drug of 
dependence (17,434 clients) than they were for opioid pharmaceuticals (8,795 clients) (Figure 
2.11). Methadone (2,186 clients) and morphine (2,136 clients) were the next most reported 
drugs of dependence; however, pharmacotherapy drugs may be subject to misreporting if a 
client’s treatment drug is reported in place of the opioid drug of dependence leading a client 
to seek treatment. In addition, differences in reporting for Victoria and Western Australia 
mean that data on opioid drug of dependence should be interpreted with caution (see 
footnotes in figures 2.11 and 2.12 for more information). 
  
Notes 
1. Clients can have up to 5 opioid drugs of dependence recorded. NSW, Qld, SA, Tas, the ACT and the NT reported 1 opioid drug of 
dependence per client. Vic reported multiple opioid drugs of dependence for a maximum of 1% of clients—these data have been included 
without amendment. WA reported multiple drugs of dependence for a maximum of 15% of clients—these data have been adjusted to allow 
comparisons between jurisdictions. Values for WA clients with multiple opioid drugs of dependence were imputed based on proportions 
reported for other WA clients. 
2. ‘Not stated/not reported’ also includes 'Inadequately described' responses. 
Source: Table A9. 
Figure 2.11: Opioid drugs of dependence reported for clients receiving pharmacotherapy on a 
snapshot day, 2013 
Heroin was the most common drug of dependence for all states and territories, except 
Tasmania and the Northern Territory, where morphine was the most common (Figure 2.12). 
Comparing states and territories, heroin was most common in the Australian Capital 
Territory (81% of all reported drugs of dependence, excluding ‘not stated’ and ‘not reported’ 
responses). All other states and territories apart from Tasmania and the Northern Territory 
had between 60% and 70% of all opioid drugs of dependence reported as heroin. 
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Notes 
1. Clients can have up to 5 opioid drugs of dependence recorded. NSW, Qld, SA, Tas, the ACT and the NT reported 1 opioid drug of 
dependence per client. Vic reported multiple opioid drugs of dependence for a maximum of 1% of clients—these data have been included 
without amendment. WA reported multiple drugs of dependence for a maximum of 15% of clients—these data have been adjusted to allow 
comparisons between jurisdictions. Values for WA clients with multiple opioid drugs of dependence were imputed based on proportions 
reported for other WA clients. 
2. ‘Not stated/not reported’ also includes 'Inadequately described' responses. 
Source: Table A9. 
Figure 2.12: Opioid drugs of dependence reported for clients receiving pharmacotherapy on a 
snapshot day, by state and territory, 2013 
Do clients stay in treatment? 
Clients interact with the pharmacotherapy treatment system in a number of ways. A client’s 
status may differ according to whether they are: receiving treatment for the first time (new), 
re-entering treatment after a lapse (readmission), continuing treatment (ongoing) or 
transferring from another state/territory jurisdiction (interstate transfer).  
Based on a snapshot day in 2013, client status data were provided for Victoria, Queensland, 
Western Australia and Tasmania (Figure 2.13). Across these 4 jurisdictions, a large majority 
of clients were classed as ongoing. This was highest in Tasmania (98%), followed by Western 
Australia (94%), Victoria (86%, excluding ‘not stated’ responses) and Queensland (67%). The 
proportion of re-admitting clients ranged from 27% in Queensland to less than 1% in 
Tasmania. New clients comprised a small proportion of clients in all 4 jurisdictions (no 
greater than 6%). 
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Note: Data were not available for NSW, SA, ACT and NT. 
Source: Table A10. 
Figure 2.13: Clients receiving pharmacotherapy on a snapshot day, by client status, and state and 
territory, 2013 
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3 Prescribers 
3.1 How are prescribers authorised? 
Opioid pharmacotherapies are prescribed by medical personnel such as general practitioners 
and medical specialists. Each state and territory has a registration process through which 
prescribers can undergo training and become registered to prescribe opioid 
pharmacotherapies to clients. Some jurisdictions, including South Australia and Victoria, 
also authorise prescribers to prescribe opioid pharmacotherapies for a small number of 
clients without undergoing the specified training. Data on all registered or authorised 
prescribers are included in this report, except for New South Wales, Western Australia and 
South Australia, where prescribers are included only if they are actively prescribing for at 
least 1 client on the snapshot day (see Table 5.2 for further details). NSW has 8 prescribers 
who prescribe in more than 1 location, and as such are counted twice. This will lead to 
slightly deflated client to prescriber ratios.  
Nationally, there were 2,025 prescribers authorised to prescribe 1 or more pharmacotherapy 
drugs in 2013 (Table 3.1). This was an increase of 257 prescribers (15%) from 2012 and 476 
(31%) since 2011. 
Of these 2,025 prescribers: 
• 71% (1,442) were authorised to prescribe more than 1 pharmacotherapy type 
• 18% (371) were authorised to prescribe methadone only 
• 6% (120) were authorised to prescribe buprenorphine-naloxone only 
• The remaining 5% (92) were located in New South Wales and were authorised to 
prescribe buprenorphine and/or buprenorphine-naloxone, but reported as 
‘Buprenorphine only’ (Table 3.1). 
The proportion of prescribers authorised to prescribe more than 1 pharmacotherapy type 
increased from 51% in 2006 to 71% in 2013 (Figure 3.1). The increase in the proportion of 
prescribers authorised to prescribe buprenorphine-naloxone only (from 1% in 2011 to 6% in 
2013) occurred mainly in South Australia and is due to the introduction of the Suboxone® 
Opioid Substitution Program (SOSP) in South Australia, discussed in more detail below. In 
Victoria, as of 2013, general practitioners can prescribe buprenorphine-naloxone for up to 5 
patients without the need to attend training (Vic Health 2013). This also had an impact on the 
increased proportion of buprenorphine-naloxone-only prescribers. 
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Note: NSW counts buprenorphine-naloxone as ‘buprenorphine’. See Chapter 5 for further details. 
Source: Table A11. 
Figure 3.1: Prescribers, by pharmacotherapy type, 2006–2013 
 
All prescribers in the Australian Capital Territory and the Northern Territory were 
registered to prescribe more than 1 drug type in 2013. In the other 6 jurisdictions, South 
Australia (58%), New South Wales (52%), Tasmania (30%) and Victoria (17%) had substantial 
proportions of prescribers registered to prescribe a single drug type only (Table 3.1). 
Between 2012 and 2013, prescriber numbers grew in all states and territories (Table A11). 
Table 3.1: Prescribers, by pharmacotherapy type, and state and territory, 2013 
Pharmacotherapy type NSW(b) Vic  Qld WA SA Tas ACT NT Australia Australia (%) 
 Number of prescribers 
Methadone only 236 119 1 4 — 11 — — 371 18.3 
Buprenorphine only(a) 92 — — — — — — — 92 4.5 
Buprenorphine-naloxone 
only n.a. 18 2 — 100 — — — 120 5.9 
More than 1 drug type 308 684 180 94  72 26 66 12 1,442 71.2 
Total (number) 636 821 183  98  172 37 66 12 2,025 100.0 
Total (per cent) 31.4 40.5 9.0 4.8 8.5 1.8 3.3 0.6 100.0 . . 
(a) NSW counts buprenorphine-naloxone as ‘buprenorphine’. See Table 5.2 for further details. 
(b) The numbers provided for NSW represent the type of drugs prescribed by active prescribers on 30 June rather than the number of 
prescribers approved to prescribe each drug type. 
Note: The states and territories may have different guidelines and policies regarding training and registration to prescribe opioid 
pharmacotherapy types. See Chapter 5 for more information.  
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3.2 Where do prescribers work? 
Prescribers are classified according to the sector in which they are working when prescribing 
pharmacotherapy drugs to clients. 
• Private prescribers work in organisations that are not controlled by government, such as 
private general practice clinics. 
• Public prescribers work in organisations that are part of government or are 
government-controlled, such as public drug and alcohol clinics and public hospitals. 
• Correctional facility prescribers work in prisons or other correctional services. 
Of the 2,025 prescribers authorised to prescribe pharmacotherapy drugs in 2013: 
• 82% (1653) were private prescribers 
• 13% (270) were public prescribers 
• 3% (67) were correctional facility prescribers 
• 2% (35) were public/private prescribers (Table 3.2). 
In 2013, Victoria had no public prescribers, and so had the highest proportion of private 
prescribers (98%) (Table 3.2). This was followed by South Australia (90% private prescribers) 
and the Australian Capital Territory (88% private prescribers). The Northern Territory had 
the highest proportion of public prescribers (67%), followed by Tasmania and Queensland 
(both 32%). 
Table 3.2: Prescribers, by prescriber type, and state and territory, 2013 
Prescriber type NSW Vic  Qld WA SA Tas ACT NT Australia 
Private prescriber 437 803 112 64 154 23 58 2 1,653 
Public prescriber 156 — 58 19 12 12 5 8 270 
Public/private prescriber(a) 28 — 5 — — — 2 — 35 
Correctional facility 15 18 8 15 6 2 1 2 67 
Total 636 821 183 98 172 37 66 12 2,025 
(a) In NSW, Qld and ACT, these figures relate to prescribing that cannot be separated into a single prescriber type. 
Note: The states and territories have different guidelines and policies regarding training and registration to prescribe opioid 
pharmacotherapy types. In South Australia, for example, 100 out of 172 prescribers treat a total of 150 clients (under the 
SOSP). See Chapter 5 for more information. 
3.3 How many clients do prescribers treat? 
Of the 47,422 clients receiving treatment on the snapshot day in June 2013, when data from 
all states and territories are combined: 
• 65% (30,680) received treatment from a private prescriber 
• 28%(13,219) received treatment from a public prescriber 
• 7% (3,265) received treatment from a correctional facility prescriber (Table 3.3). 
These proportions have remained stable since 2006 (Figure 3.2). 
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Source: Table A12. 
Figure 3.2: Clients receiving pharmacotherapy on a snapshot day, by prescriber type, 2005–2013 
 
Private prescribers treated the majority of clients in New South Wales, Victoria, Western 
Australia and South Australia. Public prescribers treated the majority of clients in 
Queensland, Tasmania, the Australian Capital Territory and the Northern Territory 
(Table 3.3). This pattern is similar to that observed in 2012 for all jurisdictions.  
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Table 3.3: Clients receiving pharmacotherapy on a snapshot day, by pharmacotherapy 
type, prescriber type, and state and territory, 2013 
Prescriber type NSW  Vic Qld WA SA Tas ACT NT Total 
  Number of clients 
  Methadone 
Private prescriber 8,461 8443 1,054 1,012 1,049 214 248 5 20,486 
Public prescriber 4,425 — 1,973 823 653 160 394 40 8,468 
Public/private prescriber(a) 209 — — — — — — — 209 
Correctional facility 1,461 791 29 292 167 1 87 — 2,828 
Total 14,556 9,234 3,056 2,127 1,869 375 729 45 31,991 
  Buprenorphine(b) 
Private prescriber 2,460 525 375 57 22 20 11 3 3,473 
Public prescriber 1,912 — 328 50 54 34 19 15 2,412 
Public/private prescriber(a) 69 — — — — — — — 69 
Correctional facility 200 6 5 — 2 1 — — 214 
Total 4,641 531 708 107 78 55 30 18 6,168 
  Buprenorphine-naloxone 
Private prescriber n.a. 4,125 1,119 638 715 75 46 3 6,721 
Public prescriber n.a. — 1190 383 421 153 115 77 2,339 
Public/private prescriber(a) n.a. — — — — — — — — 
Correctional facility n.a. 71 20 31 96 1 — 4 223 
Total n.a. 4,196 2,329 1,052 1,232 229 161 84 9,283 
  Total (all pharmacotherapy drugs) 
Private prescriber 10,921 13,093 2,548 1,707 1,786 309 305 11 30,680 
Public prescriber 6,337 — 3,491 1,256 1,128 347 528 132 13,219 
Public/private prescriber(a) 278 — — — — — — — 278 
Correctional facility 1,661 868 54 323 265 3 87 4 3,265 
Total 19,197 13,961 6,093 3,286 3,179 659 920 147 47,442 
 
Total (per cent all pharmacotherapy drugs) 
Private prescriber 56.9 93.8 41.8 51.9 56.2 46.9 33.2 7.5 64.7 
Public prescriber 33.0 — 57.3 38.2 35.5 52.7 57.4 89.8 27.9 
Public/private prescriber(a) 1.4 — — — — — — — 0.6 
Correctional facility 8.7 6.2 0.9 9.8 8.3 0.5 9.5 2.7 6.9 
Total (%) 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
(a) These figures relate to prescribing that cannot be separated into public or private prescribers. 
(b) NSW counts buprenorphine-naloxone as ‘buprenorphine’. See Chapter 5 for further details. 
Clients per prescriber 
On a snapshot day in 2013, 2,025 prescribers were treating an average of 23 clients each 
(compared to an average of 26 clients in 2012) (Figure 3.3). Low growth in client numbers 
(less than 2% between 2012 and 2013) coupled with relatively high growth in prescriber 
numbers (15% between 2012 and 2013) meant that the client-to-prescriber ratio fell in 2013. 
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This continues a recent trend, with the client-to-prescriber ratio falling for the last 3 collection 
years. 
Between 2012 and 2013, the number of clients per prescriber fell in all states and territories 
(Figure 3.3). In relative terms, Queensland had a notable decrease (from 44 to 33), as did the 
Northern Territory (from 15 to 12) and Victoria (21 to 17). In South Australia, the substantial 
decrease in the number of clients per prescriber since 2012 was maintained. 
 
 
Note: In South Australia, the decline in clients per prescriber is attributed to the introduction of the SOSP. On a snapshot day in 2013, 100 
prescribers registered under the SOSP treated a total of 150 clients, while the remaining 72 prescribers treated a total of 3,029 clients. 
Source: Table A13. 
Figure 3.3: Ratio of clients to prescriber, by state and territory, on a snapshot day, 2005–2013 
 
In 2013, prescribers working in the public sector had, on average, about 2 and a half times as 
many clients as prescribers working in the private sector (49 clients per prescriber compared 
with 19) (Figure 3.4). Public prescribers in the Australian Capital Territory (106 clients) and 
South Australia (94 clients) had a relatively high average number of clients. Private 
prescribers had a lower average number of clients than public prescribers in all states and 
territories except for Victoria, which had no public prescribers. 
Prescribers working in correctional facilities had an average of 49 clients nationally, but at a 
state and territory level this varied widely, from 2 clients per prescriber in Tasmania and the 
Northern Territory to 111 clients per prescriber in New South Wales (Figure 3.4). 
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Source: Table A14. 
Figure 3.4: Ratio of clients to prescribers, by prescriber type and state and territory, on a snapshot 
day, 2013 
3.4 Does drug treatment vary between sectors? 
Treatment type 
In 2013, methadone was the most commonly prescribed drug in all sectors (Figure 3.5). 
However, prescribers in correctional facilities were far more likely to prescribe methadone 
(87% of clients) when compared with private (67%) or public prescribers (64%). Private 
prescribers were the most likely to prescribe buprenorphine-naloxone (22%) compared with 
public (18%) or correctional facility (7%) prescribers. Given that clients prescribed 
buprenorphine-naloxone in New South Wales are reported as receiving buprenorphine, the 
proportion of clients receiving buprenorphine-naloxone nationally (as shown in Figure 3.5) is 
likely to be an underestimate. 
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Notes 
1. NSW counts buprenorphine-naloxone as ‘buprenorphine’. See Chapter 5 for further details. 
2.  In Qld, only female inmates receive opioid pharmacotherapy treatment. 
Source: AIHW analysis of Table A12. 
Figure 3.5: Clients receiving pharmacotherapy on a snapshot day, by pharmacotherapy type and 
prescriber type, 2013 
Client characteristics 
The client group treated by particular prescriber types can vary depending on the 
demographic features of the clients. Based on 2013 unit record data from 6 states/territories, 
correctional facility prescribers were more likely to treat younger clients (Figure 3.6)—the  
proportion of clients aged 50 and over that were treated by correctional facilities was about a 
quarter of that seen for all prescribers. Correctional facilities treated clients aged under 30 at 
over twice the rate seen for all prescribers. Public and private prescribers served similar 
client groups, with public/private prescribers serving a slightly older group of clients.  
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Notes 
1. Unit record data were used to produce this figure. Records were available for 58% of total clients receiving pharmacotherapy on a snapshot 
day in 2013. 
2. The figure includes data from NSW, SA, WA, Tas, ACT and NT. Vic and Qld data were not available. 
Source: Table A15. 
Figure 3.6: Clients receiving pharmacotherapy treatment on a snapshot day, by prescriber type and 
age group, 2013 
 
Public, private and public/private prescriber types were generally similar in terms of the 
proportion of male and female clients treated, each treating about twice as many males as 
females (Table A15). Correctional facilities were different, with about 9 in 10 clients being 
male. 
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4 Dosing points 
A dosing point is the site where clients receive the medication prescribed for them. In 
general, clients attend a dosing point and receive 1 dose of medication, which they take 
under supervision, in order to reduce the risks of diversion, misuse or overdose. However, 
stable clients may be authorised to take home 1 or more ‘takeaway’ doses for use on 
subsequent days (DoHA 2007). 
4.1 What are the numbers and types of dosing 
points? 
In 2012–13 there were 2,355 dosing points in Australia, an increase of 129 (6%) from 2011–12 
(Table A16). In the same period the number of dosing points rose in all states and territories. 
Nationally, in 2012–13 the majority of dosing points were pharmacies (88%), which were the 
most common dosing point sites in all states and territories (Table 4.1). These proportions are 
very similar to those observed in previous years.  
Table 4.1: Dosing point sites, by state and territory, 2012–13 
Dosing point sites NSW(a) Vic Qld WA SA Tas ACT NT Australia Australia (%) 
Public clinic 36 — 11 1 2 2 1 2 55 2.3 
Private clinic 12 — 7 — — — — — 19 0.8 
Pharmacy 680 455 411 241 193 58 32 8 2,078 88.2 
Correctional facility 1 11 5 2 8 1 1 1 30 1.3 
Other(b) 75 16 77 2 2 1 — — 173 7.3 
Total (number) 804 482 511 246 205 62 34 11 2,355 100.0 
Total (%) 34.2 20.5 21.7 10.4 8.7 2.6 1.4 0.5 100.0 . . 
(a) See Chapter 5 for more information about NSW. NSW correctional dosing points are reported under a single facility. 
(b) The category ‘Other’ includes hospitals, mobile dosing sites, community health clinics, non-government organisations, 
doctors’ surgeries and dosing points ‘not stated’. 
4.2 What is the relationship between clients and 
dosing points? 
Of the 47,442 clients receiving treatment on the snapshot day in June 2013, the majority (71%) 
dosed at a pharmacy. Other common sites for dosing were private and public clinics (8% of 
clients each) and correctional facilities (7%) (Table A17).  
Clients per dosing point 
On the snapshot day in June 2013, an average of 20 clients dosed at each dosing point site 
(Figure 4.1). However, this varied greatly by the type of dosing point. For example, more 
than 10 times as many clients dosed at private clinics, on average, than at pharmacies (194 
clients per dosing point compared to 16). An average of 107 clients dosed at correctional 
facilities, but this number is inflated as New South Wales reports all correctional dosing 
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point sites under a single facility. If New South Wales data are excluded, an average of 52 
clients were dosed at correctional facilities (tables 4.1 and A17). 
 
Note: NSW reports all correctional dosing point sites under a single facility. 
Source: Table 4.1 and AIHW analysis of Table A17. 
Figure 4.1: Ratio of clients to dosing point sites, on a snapshot day, 2013 
Nationally, the ratio of clients per dosing point rose from around 19 in 2006, peaking at 
around 21 from 2010 to 2012 (Figure 4.2). In 2013, the ratio decreased slightly to 20. At a state 
and territory level, the ratio of clients per dosing point rose or remained relatively stable 
between 2006 and 2012. In 2013, Victoria had the highest ratio of clients per dosing point (29), 
followed by the Australian Capital Territory (27) and New South Wales (24) (Figure 4.2).  
 
Source: Table A13. 
Figure 4.2: Ratio of clients to dosing points on a snapshot day, by state and territory, 2006–2013 
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Drug type 
While the majority of clients were dosed at pharmacies, a larger proportion of clients who 
received buprenorphine-naloxone were dosed at a pharmacy (84%) than those receiving 
methadone (71%) or the buprenorphine-only product (55%). A larger proportion of clients 
who received methadone were dosed in a correctional facility (9%) than those who received 
buprenorphine only (4%) or buprenorphine-naloxone only (3%) (Figure 4.3). These 
proportions have remained similar over time (Table A18). The proportion of clients dosed 
with buprenorphine-naloxone may be higher than reported, given that clients receiving 
buprenorphine-naloxone in New South Wales are reported as receiving buprenorphine.  
 
Notes 
1. NSW counts buprenorphine-naloxone as ‘buprenorphine’. See Chapter 5 for further details. 
2. The category ‘Other’ includes mobile dosing sites, non-government organisations, doctors’ surgeries and dosing points ‘not stated’. 
3. In Qld, the category ‘Not stated’ refers to clients who received their pharmacotherapy drug at a dosing point before the ‘snapshot/specified’ 
day—that is, they received a takeaway dose. In SA, ‘Not stated’ refers to clients registered to receive treatment but who failed to dose. 
Source: Table A18. 
Figure 4.3: Clients receiving pharmacotherapy on a snapshot day, by pharmacotherapy type and 
dosing point site, 2013 
Table A17 provides a further breakdown of clients by pharmacotherapy type, dosing points, 
and state and territory. 
Client characteristics 
As with prescriber types, the characteristics of the client group treated at particular dosing 
point types are not uniform. Based on data from 6 states/territories, an older client group 
dosed at pharmacy dosing points in 2013 compared with other dosing point types, with a 
lower proportion of clients aged under 30 and a higher proportion of clients aged 50 and 
over (Figure 4.4). In contrast, a much younger client group dosed at correctional facility 
dosing points than other dosing point types. The client groups dosed at public clinics, 
private clinics and hospitals were similar. 
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Notes 
1. Unit record data were used to produce this figure. Records were available for 58% of total clients receiving pharmacotherapy on a snapshot 
day in 2013. 
2. The figure includes data from NSW, SA, WA, Tas, ACT and NT. Vic and Qld data were not available. 
Source: Table A19. 
Figure 4.4: Clients receiving pharmacotherapy on a snapshot day, by dosing point type and age 
group, 2013 
 
With the exception of correctional facilities, about twice as many males compared to females 
dosed at each dosing point type, reflecting the overall proportion of males and females 
receiving pharmacotherapy treatment. The proportion of male clients ranged from 58% for 
hospital dosing points to 72% for private clinic dosing points (Table A19). Correctional 
facility dosing points provided pharmacotherapy to 7 male clients for every female client (in 
Queensland, however, only females can receive opioid pharmacotherapy in correctional 
facilities). 
There are a number of different pathways that clients take from where they are prescribed 
pharmacotherapy to where they are dosed their treatment. For example, on a snapshot day 
in 2013, the large majority of clients dosed at public clinics were prescribed by public 
prescribers (Table 4.2). Likewise, almost all clients dosed at private clinics were dosed by 
private prescribers. For clients dosed at pharmacies, about 2 in 5 were prescribed by public 
prescribers and about 3 in 5 by private prescribers. 
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Table 4.2: Clients receiving pharmacotherapy treatment on a snapshot day, by dosing point 
type and prescriber type, 2013 (per cent) 
  Dosing point type 
Prescriber type 
Public 
clinic 
Private 
clinic Pharmacy 
Correctional 
facility Hospital Other 
Not 
stated 
All 
dosing 
points 
Public prescriber 10.2 0.4 18.6 0.3 0.7 1.2 4.1 35.5 
Private prescriber 2.2 10.7 32.0 0.3 0.3 2.9 6.5 54.9 
Public/private prescriber — — 0.9 — — 0.1 — 1.0 
Correctional facility 0.1 — — 7.2 — 0.2 1.0 8.6 
Total 12.6 11.1 51.5 7.9 1.0 4.3 11.6 100.0 
Notes 
1. Unit record data were used to produce this table. Records were available for 58% of total clients receiving 
pharmacotherapy on a snapshot day in 2013. 
2. The table includes data from NSW, SA, WA, Tas, ACT and NT. Vic and Qld data were not available. 
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5 Explanatory notes 
A brief overview of the Australian opioid pharmacotherapy system is in Chapter 1. The 
states and territories administer the system, and this chapter has further information about 
the different policies and guidelines in each jurisdiction. It also includes information about 
changes to the NOPSAD data collection since its inception. 
Data collection by states and territories 
State and territory governments use different methods to collect data about the clients, 
prescribers and dosing points associated with the opioid pharmacotherapy system. These 
methods are driven by differences between the states and territories in relation to legislation, 
information technology systems and resources. The differences may result in discrepancies 
when comparing one state or territory with another. Differing administrative features 
adopted by each state and territory are outlined in Table 5.1 and methodological features in 
Table 5.2.  
Table 5.1: Administrative features of the NOPSAD collection in each state and territory 
State/territory  Administrative features  
New South Wales Prescribers authorised to prescribe methadone can additionally be approved to prescribe 
buprenorphine, but not vice versa. Medical practitioners who manage up to 5 clients do not require an 
approval to prescribe drugs of addiction under s. 28A of the Poisons and Therapeutic Goods Act 1966 
(NSW) and are not required to complete pharmacotherapy training. Those who are not 
accredited/approved prescribers may prescribe up to 5 ‘stable’ patients; that is, a patient may be 
transferred to them, but they cannot induct a person onto treatment. 
Victoria  The Victorian pharmacotherapy system is essentially community-based, other than for inpatients in 
hospitals and in prisons. Although a small number of services receive government funding, services 
are independent bodies and are not managed directly by government.  
As of 2013, general practitioners can prescribe buprenorphine-naloxone for up to 5 patients without the 
need to attend specific training (Vic Health 2013). In addition, changes have been made to allow 
greater flexibility for prescribers to make collaborative decisions with pharmacists regarding takeaway 
pharmacotherapy doses. 
Queensland  — 
Western Australia  Prescriber training is provided for all pharmacotherapies currently available.  
South Australia Policies were introduced in 2011 permitting any medical practitioner to be authorised to prescribe 
buprenorphine-naloxone for up to 5 patients for the treatment of opioid drug dependence. This program 
is known as the Suboxone® Opioid Substitution Program (SOSP). Authorities granted by the Drugs of 
Dependence Unit are still required to be held before starting treatment with buprenorphine-naloxone, 
and the usual program rules for all pharmacotherapy programs remain in force. 
Buprenorphine-naloxone film is the only drug option authorised for this program. A prescriber can treat 
up to a maximum of 5 patients with buprenorphine-naloxone film before having to undertake 
accreditation by Drug and Alcohol Services South Australia and formal approval by the Drugs of 
Dependence Unit to be an accredited prescriber via the Opioid Dependence Substitution Program 
(ODSP). A prescriber cannot provide treatment with buprenorphine alone or methadone liquid without 
first being accredited. 
Tasmania In Tasmania, pharmacotherapy training is provided separately for each pharmacotherapy drug. 
Australian Capital 
Territory 
All pharmacists are required to attend training in ‘Risk Management of the Process of Dosing Opioid 
Dependent Consumers’ before they start dosing clients. This training is conducted by the Principal 
Pharmacist within the Health Directorate’s Alcohol and Drug Service. 
(continued) 
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Table 5.1 (cont.): Administrative features of the NOPSAD collection in each state and territory 
State/territory  Administrative features  
Northern Territory Prescribers complete an ‘Application for authority to prescribe a restricted S8 substance for the 
treatment of addiction’ and submit the form with a photograph of the client to the Department of Health, 
Poisons Control. A contract between the client, prescriber and supplying pharmacy is also required for 
all applications for maintenance treatments. The information provided is assessed against data held in 
the Drug Monitoring System database. Non-standard applications are required to be submitted to the 
S8 and Restricted S4 Substances Clinical Advisory Committee for advice before a decision can be 
made on whether to issue the authorisation and whether special conditions need to apply. The 
prescriber is not permitted to prescribe until they receive a signed authorisation document (usually 
delivered by facsimile). When the prescriber is no longer treating the client, they are required to notify 
Poisons Control—this may be done by marking the authorisation/copy of application document as 
ceased, or by other written advice. 
Table 5.2: Methodological differences for the NOPSAD collection in each state and territory 
State/territory  Methodological notes 
National The ‘snapshot day’ varies between states and territories, but allows the number of clients to be 
estimated at a single point in time. Data collected for a snapshot day are likely to result in an 
underestimate of total clients receiving pharmacotherapy within a year. In general, all clients receiving 
their pharmacotherapy dose in-person on the snapshot day are counted; however, not all 
states/territories are able to count clients receiving a take-away dose on the snapshot day. 
New South Wales The Pharmaceutical Drugs of Addiction System (PHDAS) is used primarily in the administration of the 
New South Wales Opioid Treatment Program. The database is used to record the authorisation of 
doctors to prescribe as part of the New South Wales Opioid Treatment Program. The PHDAS also 
records client admissions to, and exits from, treatment, as well as details of approved prescribers and 
dosing points. For these reasons, the PHDAS is characterised by continual fluctuations and data 
extracted at different times for the same period may not be the same. However, while delays in 
reporting entries to the program, exits from the program and changes in the status of dosing points 
cause short-term fluctuations in the database, these flatten out over the course of a full year. 
Clients prescribed buprenorphine-naloxone are counted under ‘buprenorphine’. 
Similarly, New South Wales data collection does not differentiate between prescribers who are 
authorised to prescribe buprenorphine and those authorised to prescribe buprenorphine-naloxone. 
Data relating to prescribers refer to active prescribers only. 
In New South Wales approved and accredited prescribers can prescribe both methadone and 
buprenorphine (including buprenorphine-naloxone). The numbers provided in Table 3.1 for New South 
Wales represent the type of drugs prescribed by active prescribers on 30 June rather than the number 
of prescribers approved to prescribe each drug type. 
Data on dosing point sites relate to sites that were dosing at least 1 client as at 30 June 2013. 
Client data are reported in New South Wales as at 30 June. 
Victoria  Data are collected from 2 sources: a half-yearly census of pharmacists who are requested to report the 
actual number of clients being dosed on a snapshot day, and the permit database, which records 
information about prescribers authorised to prescribe pharmacotherapy drugs, as well as demographic 
information about clients accessing pharmacotherapy treatment. These 2 data sources cannot be 
linked.  
The number of prescribers in Victoria is determined by adding the number of prescribers registered for 
that year to the number of existing prescribers. 
In 2013, data were not provided for age and sex by individual pharmacotherapy drug type. Age and 
sex data for all pharmacotherapy drugs (combined) were provided. In previous years, these data were 
estimated by Victoria. 
In Victoria, data relating to the Indigenous status of clients are not available.  
Client data are reported in Victoria on a snapshot day. 
(continued) 
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Table 5.2 (cont.): Methodological differences for the NOPSAD collection in each state and territory 
Queensland  Data are collected monthly from pharmacists and entered into a central database managed by 
Medicines Regulation and Quality. Data are also collected from administrative ‘Admission’ and 
‘Discharge’ forms. Queensland totals may vary slightly due to these data source differences. For 
example, a client may be counted as registered and having received a dose on the snapshot day, but a 
dosing point cannot be assigned because the dose consumed on that day was a takeaway dose. 
The total number of prescribers for Queensland includes those from private practice, public clinics, 
correctional facilities and government medical offices. 
Client data are reported in Queensland on a snapshot day.  
Western Australia  Data are collected from the monthly reports received from pharmacies and other dosing sites 
authorised to participate in the Community Program for Opioid Pharmacotherapy (C-POP). The dosing 
data are entered into the Pharmaceutical Services Branch’s Monitoring of Drugs of Dependence 
System (MODDS) database. Data are also collected from the ‘Application for authority’, ‘Authority to 
prescribe’ and ‘Termination of treatment’ forms. The number of clients receiving pharmacotherapy 
treatment is reported through the month of June.  
The total number of prescribers includes those treating at least 1 client as at 30 June 2013 in private 
practice, public clinics and correctional facilities. 
In Western Australia, data relating to the Indigenous status of clients are not available. 
Client data are reported in Western Australia for the entire month of June. Specifically, pharmacies 
supply information at the end of June relating to the last dose supplied to the patient. If a patient 
changes pharmacies mid-month, it is possible that they appear on 2 pharmacies’ monthly transaction 
reports and are counted twice. Before 2005, Western Australia reported clients over a year. 
South Australia  Data are collected from the forms ‘Application for authority’, ‘Termination of treatment’ and ‘Request for 
additional methadone/buprenorphine takeaway’, which are entered into a central database system at 
the Drugs of Dependence Unit, Medicines and Technology Policy and Programs, SA Health. 
Information from dispensed prescriptions is also collected electronically from pharmacists on a monthly 
basis by the Drugs of Dependence Unit. 
From 2011, data have been collected via a half-yearly survey completed by pharmacists and reported 
on a snapshot day. Other data are drawn from the Drugs of Dependence Unit’s Drugs of Misuse 
Surveillance System and are about those clients registered for treatment on the snapshot day (but who 
may not actually receive treatment on that day). 
Clients who did not enter a dosing point on the snapshot day are reported as ‘other’ when describing 
clients by dosing point site.  
All tables include ODSP and SOSP clients and prescribers. 
In South Australia, data relating to prescribers refer to active prescribers only. 
Tasmania  Data are collected monthly from pharmacists participating in the Tasmanian Opioid Pharmacotherapy 
Program, and entered into the Drug and Alcohol Pharmacy Information System (DAPIS). This central 
database is managed through the Pharmaceutical Services Branch, and is a ‘live’ database, from 
which a snapshot for any day can be taken. Data from DAPIS are made available for 
management-style reporting from an intranet-based dashboard system. 
Client data are reported in Tasmania on a snapshot day. 
Australian Capital 
Territory 
Client participation data are collected manually from the Health Directorate’s Alcohol and Drug 
Services spread sheets and from Medication Administration Chart (MAC Sheets) which are provided 
by the community pharmacies. General practitioner and pharmacy participation data are also collated 
from the MAC Sheets. 
Client data are reported in the Australian Capital Territory on a snapshot day. 
Northern Territory  Client data are reported in the Northern Territory on a snapshot day. 
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Table 5.3: Policies and guidelines for opioid pharmacotherapy 
State/territory  Policies and guidelines for opioid pharmacotherapy  
National • National pharmacotherapy policy for people dependent on opioids 2007 
New South Wales • Opioid Treatment Program Clinical Guidelines 2006 for Methadone and Buprenorphine 
Treatment of Opioid Dependence  
Victoria • Policy for Maintenance Pharmacotherapy for Opioid Dependence  
Queensland • Queensland Opioid Treatment Program: clinical guidelines 2012 
Western Australia • Western Australia Clinical Policies and Procedures for the Use of Methadone and 
Buprenorphine in the Treatment of Opioid Dependence—3rd Edition 
• Operational Directive 0255/09 Management of C-POP Patients in a Hospital Setting 
South Australia • Information for medical practitioners acting as a locum for an accredited community ODSP 
prescriber 
• Guidelines for action to be taken in response to serious breaches of the drug treatment 
programs—ODSP and SOSP 
• Policy for non-supervised dosing of methadone and buprenorphine in drug treatment 
programs 
• Policy for split doses methadone in the ODSP 
• Policy relating to the use of buprenorphine in the ODSP 
• Protocol for drug treatment program transfer to South Australia 
• Protocol for drug treatment program transfer interstate/territory 
• Validity of a South Australia prescription for the ODSP in another state/territory 
• Validity of an interstate prescription for the ODSP in South Australia 
• SOSP Guidelines—an information handout for medical practitioners in South Australia 
• Information for a prescriber acting in the absence of the Authority holder (paediatrician) 
accredited to treat Neonatal Abstinence Syndrome (NAS) 
Tasmania • Tasmanian Opioid Pharmacotherapy Policy and Clinical Practice Standards, 2012 
Australian Capital Territory • The ACT Opioid Maintenance Treatment Guidelines 
Northern Territory • Northern Territory Schedule 8 and Restricted Schedule 4 Substances Policy and Clinical 
Practice Guidelines 
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Table 5.4: History of data reported for the NOPSAD collection, 2005–2013  
  2005 2006 2007 2008 2009 2010 2011 2012 2013 
Data form Aggregated Aggregated Aggregated Aggregated Aggregated Aggregated Aggregated 
Aggregated + 
Unit records 
Aggregated + 
Unit records 
Data item Client items 
Age 
 
        
  Not available in NT Not available in NT Not available in 
NT 
Not available in 
NT 
Not available in 
NT 
   
Sex 
 
        
Indigenous status 
 
        
   Not available in Vic, 
WA, SA, Tas and NT 
 Not available in 
Vic, WA, Tas and 
NT 
 Not available in 
Vic, WA, Tas and 
NT 
 Not available 
in Vic, WA, Tas 
and NT 
 Not available in 
Vic, WA, Tas 
and NT 
 Not available 
in Vic, WA, 
Tas and NT 
 Not available in 
Vic and WA 
 Not available in 
Vic and WA 
Pharmacotherapy 
drug type 
         
Methadone and 
buprenorphine data 
collected 
Buprenorphine-
naloxone collection 
begins. NSW and Qld 
clients prescribed 
buprenorphine-
naloxone are counted 
under 'buprenorphine' 
NSW and Qld 
clients prescribed 
buprenorphine-
naloxone are 
counted under 
'buprenorphine' 
2008 onward, 
NSW clients 
prescribed 
buprenorphine-
naloxone are 
counted under 
'buprenorphine' 
     
Prescriber type          
Dosing point type          
   2008 onward, Qld 
included 'Other' 
category to 
capture clients not 
physically dosed 
on snapshot day 
     
Opioid drug(s) of 
dependence 
         
Client status 
        
 
 
        
Not available in 
NSW, SA, ACT 
and NT.  
General 
comments on 
client data items 
SA client data not 
provided for 
individual 
pharmacotherapy 
drug types. Before 
2005, WA reported 
client data over a 1- 
year period. 
  SA revised total 
number of clients 
for 2006 and 
2007. This 
revision resulted 
in change to 
overall client 
numbers 
    Vic client age 
and sex data not 
provided for 
individual drug 
types 
(continued) 
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Table 5.4 (cont.): History of data reported for the NOPSAD collection, 2005–2013 
  2005 2006 2007 2008 2009 2010 2011 2012 2013 
Data item Prescriber items 
Type 
     
    
Drug(s) 
prescribed          
 Methadone and 
buprenorphine data 
collected 
Buprenorphine-
naloxone 
collection begins. 
NSW and Qld do 
not differentiate 
between 
prescribers of 
buprenorphine 
and 
buprenorphine-
naloxone 
NSW and Qld do 
not differentiate 
between 
prescribers of 
buprenorphine and 
buprenorphine-
naloxone 
2008 onward, 
NSW do not 
differentiate 
between 
prescribers of 
buprenorphine 
and 
buprenorphine-
naloxone 
 Vic prescribers 
numbers 
revised for 
2006–2009  
 Vic prescribers 
numbers 
revised for 
2011  
 
Data item Dosing point items 
Type 
 
        
 
 
From 2006 
onward, NSW 
correctional facility 
dosing point types 
are recorded 
under 1–2 sites 
   Vic dosing 
point numbers 
revised for 
2005–06 to 
2007–08  
 Vic dosing 
point numbers 
revised for 
2010–11  
 
      334 SA clients 
did not report 
dosing point 
type and were 
recorded as 
'Other' 
   
Locality                 
General 
comments 
              Unit record 
data were 
provided by 
SA, Tas, NT 
and ACT. Data 
were not used 
in the 
NOPSAD 
report due to 
limitations in 
coverage. 
Unit record data 
were provided by 
NSW, WA, SA, 
Tas, NT and 
ACT. 
Note:  indicates that the data item was provided in the given collection year.
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Appendix A: Supporting tables  
Table A1: Clients receiving pharmacotherapy on a snapshot day, by state and territory, 1998–2013 
Year NSW Vic Qld WA SA Tas ACT NT Australia 
Clients per 
10,000 
population, 
Australia 
Australia 
population 
1998 12,107 5,334 3,011 1,654 1,839 306 406 — 24,657 13 18,607,584 
1999 12,500 6,700 3,341 2,449 1,985 370 559 2 27,906 15 18,812,264 
2000 13,594 7,647 3,588 2,140 2,198 423 615 32 30,237 16 19,028,802 
2001 15,069 7,743 3,745 2,307 2,522 464 641 25 32,516 17 19,274,701 
2002 15,471 7,700 3,896 3,602 2,417 513 590 21 34,210 18 19,495,210 
2003 16,165 8,685 4,289 4,079 2,486 498 686 98 36,986 19 19,720,737 
2004 15,719 10,003 4,470 4,437 2,706 576 748 82 38,741 19 19,932,722 
2005 16,469 10,753 4,440 2,883 2,857 588 764 183 38,937 19 20,176,844 
2006 16,355 10,736 4,637 2,888 2,823 602 790 134 38,965 19 20,450,966 
2007 16,348 11,051 4,309 2,822 2,834 600 765 114 38,843 19 20,827,622 
2008 17,168 11,821 4,899 2,908 3,052 588 786 125 41,347 19 21,249,199 
2009 17,868 12,576 5,116 3,187 3,151 634 792 121 43,445 20 21,691,653 
2010 19,114 13,185 5,688 3,342 3,210 620 811 108 46,078 21 22,031,750 
2011 18,831 13,755 5,702 3,382 3,183 645 825 123 46,446 21 22,340,024 
2012 18,715 14,035 5,819 3,273 3,215 626 893 121 46,697 21 22,683,573 
2013 19,197 13,961 6,093 3,286 3,179 659 920 147 47,442 21 23,130,931 
Note: Population data are sourced from ABS Australian Demographic Statistics, June 1998–2013 (ABS 2014a). 
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Table A2: Population rates for clients receiving pharmacotherapy on a snapshot day, by state and 
territory, 2011–2013 
Jurisdiction Clients Population 
Clients per 10,000 
population 
 
2013 
NSW 19,197 7,407,682 26 
Vic 13,961 5,737,615 24 
Qld 6,093 4,658,557 13 
WA 3,286 2,517,165 13 
SA 3,179 1,670,834 19 
Tas 659 513,012 13 
ACT 920 383,375 24 
NT 147 239,507 6 
Australia 47,442 23,130,931 21 
 
2012 
NSW 18,715 7,290,345 26 
Vic 14,035 5,623,492 25 
Qld 5,819 4,560,059 13 
WA 3,273 2,430,252 13 
SA 3,215 1,654,778 19 
Tas 626 512,019 12 
ACT 893 374,658 24 
NT 121 234,836 5 
Australia 46,697 22,683,573 21 
 
2011 
NSW 18,831 7,303,690 26 
Vic 13,755 5,624,090 24 
Qld 5,702 4,580,725 12 
WA 3,382 2,346,410 14 
SA 3,183 1,657,001 19 
Tas 645 510,560 13 
ACT 825 365,421 23 
NT 123 230,172 5 
Australia 46,446 22,620,554 21 
Note: Population data are sourced from ABS Australian Demographic Statistics, June 2011–2013 (ABS 2014a). 
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Table A3: Clients receiving pharmacotherapy on a snapshot day, by pharmacotherapy type, and 
state and territory, 2006–2013 
Pharmacotherapy drug 
type NSW Vic Qld WA SA Tas ACT NT Australia 
 
2013 (number) 
Methadone 14,556 9,234 3,056 2,127 1,869 375 729 45 31,991 
Buprenorphine(a) 4,641 531 708 107 78 55 30 18 6,168 
Buprenorphine-naloxone n.a. 4,196 2,329 1,052 1,232 229 161 84 9,283 
Total 19,197 13,961 6,093 3,286 3,179 659 920 147 47,442 
 
2013 (%) 
Methadone 75.8 66.1 50.2 64.7 58.8 56.9 79.2 30.6 67.4 
Buprenorphine(a) 24.2 3.8 11.6 3.3 2.5 8.3 3.3 12.2 13.0 
Buprenorphine-naloxone n.a. 30.1 38.2 32.0 38.8 34.7 17.5 57.1 19.6 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
Per cent of all clients 40.5 29.4 12.8 6.9 6.7 1.4 1.9 0.3 100.0 
  2012 (%) 
Methadone 76.1 66.5 51.6 66.7 58.7 51.1 82.3 29.8 68.0 
Buprenorphine(a) 23.9 4.2 13.7 2.9 7.9 10.7 4.0 11.6 13.5 
Buprenorphine-naloxone n.a. 29.4 34.8 30.4 33.4 38.2 13.7 58.7 18.5 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
Per cent of all clients 40.1 30.1 12.5 7.0 6.9 1.3 1.9 0.3 100.0 
 
2011 (%) 
Methadone 77.8 65.7 52.5 67.1 61.5 65.0 79.9 25.2 68.9 
Buprenorphine(a) 22.2 4.7 15.4 4.0 11.0 8.7 5.5 15.4 13.6 
Buprenorphine-naloxone n.a. 29.6 32.1 28.9 27.4 26.4 14.7 59.3 17.5 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
Per cent of all clients 40.5 29.6 12.3 7.3 6.9 1.4 1.8 0.3 100.0 
  2010 (%) 
Methadone 78.7 64.3 53.7 67.9 60.6 69.7 77.9 31.5 69.2 
Buprenorphine(a) 21.3 6.2 14.0 3.8 13.4 8.2 7.4 13.9 13.8 
Buprenorphine-naloxone n.a. 29.5 32.3 28.3 26.0 22.1 14.7 54.6 17.0 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
Per cent of all clients 41.5 28.6 12.3 7.3 7.0 1.3 1.8 0.2 100.0 
 
2009 (%) 
Methadone 80.7 62.5 55.0 68.2 62.0 74.4 78.9 38.8 70.1 
Buprenorphine(a) 19.3 8.5 14.7 4.6 14.9 11.8 7.1 14.0 13.8 
Buprenorphine-naloxone n.a. 29.0 30.3 27.2 23.1 13.7 14.0 47.1 16.1 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
Per cent of all clients 41.1 28.9 11.8 7.3 7.3 1.5 1.8 0.3 100.0 
(continued) 
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Table A3 (cont.): Clients receiving pharmacotherapy on a snapshot day, by pharmacotherapy 
type, and state and territory, 2006–2013 
Pharmacotherapy drug 
type NSW Vic Qld WA SA Tas ACT NT Australia 
  2008 (%) 
Methadone 81.4 60.6 56.1 68.6 63.2 81.6 76.0 39.2 70.0 
Buprenorphine(a) 18.6 10.2 14.1 6.2 18.5 9.2 11.3 18.4 14.5 
Buprenorphine-naloxone n.a. 29.2 29.9 25.2 18.3 9.2 12.7 42.4 15.5 
Total 100.0 100.0 100.1 100.0 100.0 100.0 100.0 100.0 100.0 
Per cent of all clients 41.5 28.6 11.8 7.0 7.4 1.4 1.9 0.3 99.9 
 
2007 (%) 
Methadone 83.2 60.0 62.1 69.3 64.2 85.3 79.3 42.1 71.7 
Buprenorphine(a) 16.8 14.0 37.9 8.7 21.7 12.2 10.8 29.8 18.0 
Buprenorphine-naloxone n.a. 26.0 — 21.9 14.1 2.5 9.8 28.1 10.3 
Total 100.0 100.0 100.0 99.9 100.0 100.0 99.9 100.0 100.0 
Per cent of all clients 42.4 28.7 11.2 7.3 6.6 1.6 2.0 0.3 100.1 
 
2006 (%) 
Methadone 83.9 59.6 61.2 64.8 62.5 86.5 75.9 53 71.4 
Buprenorphine(a) 16.1 26.8 38.8 18.8 30.9 13.5 24.1 30.6 23.2 
Buprenorphine-naloxone n.a. 13.6 — 16.4 6.6 — — 16.4 5.5 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.1 
Per cent of all clients 42.3 27.8 12.0 7.5 6.5 1.6 2.0 0.3 100.0 
(a) NSW counts buprenorphine-naloxone as ‘buprenorphine’. See Chapter 5 for further details. 
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Table A4: Clients receiving pharmacotherapy on a snapshot day, by age group and 
pharmacotherapy type, 2006–2013 
Age group (years) Methadone Buprenorphine(a) 
Buprenorphine-
naloxone All drug types  
 
2013 (number)(b) 
Under 30  2,009 737 655 5,382 
30–39  7,648 2,239 2,158 18,225 
40–49  7,329 1,711 1,502 14,543 
50 and over 5,768 950 712 9,212 
Not stated 3 0 60 80 
Total 22,757 5,637 5,087 47,442 
 2013 (%)(b) 
Under 30  8.8 13.1 12.9 11.3 
30–39  33.6 39.7 42.4 38.4 
40–49  32.2 30.4 29.5 30.7 
50–59  22.2 14.5 12.3 17.0 
60 and over 3.1 2.3 1.7 2.4 
Not stated 0.0 0.0 1.2 0.2 
Total 100.0 100.0 100.0 100.0 
  2012 (%) 
Under 30  11.8 15.2 15.5 13.0 
30–39  37.5 40.9 44.2 39.2 
40–49  30.8 28.6 28.0 30.0 
50–59  17.8 13.6 10.8 15.9 
60 and over 2.0 1.7 1.3 1.8 
Not stated 0.1 0.0 0.1 0.1 
Total 100.0 100.0 100.0 100.0 
  2011 (%) 
Under 30  14.0 17.4 18.0 15.1 
30–39  38.3 41.1 44.4 39.7 
40–49  30.0 27.6 26.3 29.0 
50–59  16.2 12.3 10.0 14.6 
60 and over 1.6 1.3 1.0 1.4 
Not stated 0.0 0.3 0.2 0.1 
Total 100.0 100.0 100.0 100.0 
(continued) 
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Table A4 (cont.): Clients receiving pharmacotherapy on a snapshot day, by age group and 
pharmacotherapy type, 2006–2013 
Age group Methadone Buprenorphine(a) 
Buprenorphine-
naloxone All drug types  
  2010 (%) 
Under 30  16.9 19.8 21.8 18.1 
30–39 38.3 42.0 44.4 39.8 
40–49 29.2 26.6 23.9 27.9 
50–59  14.6 10.7 9.0 13.1 
60 and over 1.1 0.9 0.7 1.0 
Not stated 0.0 0.0 0.1 0.01 
Total 100.0 100.0 100.0 100.0 
  2009 (%) 
Under 30  16.6 21.7 20.3 17.9 
30–39  38.6 41.8 44.5 40.0 
40–49  30.1 26.0 25.5 28.8 
50–59  13.9 9.7 8.9 12.5 
60 and over 0.9 0.7 0.7 0.8 
Total  100.0 100.0 100.0 100.0 
 2008 (%) 
Under 30  21.2 27.7 28.7 23.3 
30–39  36.9 40.1 42.5 38.2 
40–49  29.3 23.5 21.9 27.3 
50–59 12.0 8.1 6.4 10.6 
60 and over 0.6 0.5 0.5 0.5 
Total 100.0 99.9 100.0 99.9 
 2007 (%) 
Under 30  20.8 27.5 25.3 22.5 
30–39  37.4 40.4 44.3 38.6 
40–49  30.1 24.0 22.6 28.3 
50–59  11.2 7.6 7.2 10.1 
60 and over 0.5 0.5 0.6 0.5 
Total 100.0 100.0 100.0 100.0 
 2006 (%) 
Under 30  25.5 35.1 36.6 28.4 
30–39  36.2 38.4 40.3 36.9 
40–49  29.3 21.1 18.8 26.9 
50–59  8.7 5.1 4.2 7.6 
60 and over 0.3 0.3 0.2 0.3 
Total 100.0 100.0 100.1 100.1 
(a) NSW counts buprenorphine-naloxone as ‘buprenorphine’. See Chapter 5 for further details. 
(b) Counts and percentages for age by individual pharmacotherapy type do not include Victorian clients in 2013. However, the 
counts and percentages for all pharmacotherapy drugs combined do include Victorian clients. 
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Table A5: Clients receiving pharmacotherapy on a snapshot day, by sex and pharmacotherapy type, 
2006–2013 
Sex Methadone Buprenorphine(a) 
Buprenorphine-
naloxone Total 
 
2013 (number)(b) 
Male 14,413 3,697 3,360 30,711 
Female 8,340 1,940 1,669 16,603 
Not stated 4 0 58 128 
Total 22,757 5,637 5,087 47,442 
 
2013 (%)(c) 
Male 63.3 65.6 66.1 64.7 
Female 36.6 34.4 32.8 35.0 
Not stated 0.0 0.0 1.1 0.3 
Total 100.0 100.0 100.0 100.0 
 
2012 (%) 
Male 64.2 65.8 65.8 64.7 
Female 35.7 34.2 34.0 35.2 
Not stated 0.2 0.0 0.2 0.2 
Total 100.0 100.0 100.0 100.0 
 
2011 (%) 
Male 64.3 66.0 66.4 64.9 
Female 35.4 33.9 33.2 34.8 
Not stated 0.3 0.1 0.4 0.3 
Total 100.0 100.0 100.0 100.0 
 
2010 (%) 
Male 64.3 66.5 62.6 64.9 
Female 35.5 33.4 37.0 34.9 
Not stated 0.2 0.1 0.3 0.2 
Total 100.0 100.0 100.0 100.0 
 
2009 (%) 
Male 64.1 67.1 66.4 64.9 
Female 35.7 32.8 33.2 34.9 
Not stated 0.2 0.1 0.4 0.2 
Total 100 100 100 100 
 
2008 (%) 
Male 63.4 67 66.7 64.4 
Female 36.1 32.8 32.6 35.1 
Not stated 0.5 0.3 0.7 0.5 
Total 100 100.1 100 100 
(continued) 
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Table A5 (cont.): Clients receiving pharmacotherapy on a snapshot day, by sex and 
pharmacotherapy type, 2006–2013 
Sex Methadone Buprenorphine(a) 
Buprenorphine-
naloxone Total 
 
2007 (%) 
Male 63.1 66.5 66.6 64.1 
Female 36.4 33.1 32.6 35.4 
Not stated 0.5 0.4 0.8 0.5 
Total 100 100 100 100 
 
2006 (%) 
Male 62.8 67.9 65.5 64.2 
Female 36.8 31.6 33.3 35.4 
Not stated 0.3 0.5 1.1 0.4 
Total 99.9 100 99.9 100 
(a) NSW counts buprenorphine-naloxone as ‘buprenorphine’. See Chapter 5 for further details. 
(b) Total number of clients in 2013 will not equal the sum of clients for individual pharmacotherapy drugs. This is due to Victoria not reporting 
sex by pharmacotherapy type. However, the total numbers (combining all pharmacotherapy drugs), do include Victorian clients. 
(c) The percentages for sex by individual pharmacotherapy type do not include Victorian clients in 2013. However, the percentages for all 
pharmacotherapy drugs combined do include Victorian clients. 
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Table A6: Clients receiving pharmacotherapy on a snapshot day, by age and sex, 
2013 (per 10,000 population) 
  Clients per 10,000 population 
Age 
(years) Male Female Total 
Age 
(years) Male Female Total 
15 0.0 0.0 0.0 53 49.8 25.4 37.5 
16 0.0 0.1 0.1 54 49.1 23.0 35.9 
17 0.1 0.0 0.1 55 44.3 21.9 33.0 
18 0.6 0.5 0.5 56 39.5 19.3 29.3 
19 1.2 1.1 1.1 57 41.8 15.6 28.6 
20 2.4 1.6 2.0 58 31.2 10.8 20.9 
21 5.8 3.4 4.6 59 24.4 11.8 18.0 
22 7.9 5.3 6.6 60 23.2 6.8 14.9 
23 12.6 7.0 9.9 61 16.3 5.5 10.9 
24 15.1 9.1 12.2 62 12.8 4.6 8.7 
25 17.4 11.5 14.5 63 9.7 2.8 6.2 
26 22.6 13.8 18.3 64 7.2 0.9 4.0 
27 24.5 16.8 20.7 65 3.6 0.9 2.3 
28 31.0 22.2 26.7 66 2.5 1.0 1.8 
29 40.5 26.8 33.7 67 1.7 0.5 1.1 
30 51.8 31.5 41.8 68 1.1 0.4 0.7 
31 53.3 33.0 43.2 69 0.4 0.6 0.5 
32 64.3 41.3 52.9 70 1.1 0.6 0.8 
33 77.0 43.8 60.5 71 0.4 0.2 0.3 
34 75.8 43.8 59.9 72 0.5 0.2 0.3 
35 79.1 45.6 62.4 73 0.2 0.0 0.1 
36 81.9 41.6 61.8 74 0.5 0.0 0.3 
37 80.3 43.2 61.8 75 0.8 0.0 0.4 
38 68.9 38.3 53.6 76 0.0 0.3 0.1 
39 71.1 36.4 53.7 77 0.3 0.0 0.2 
40 75.0 37.2 56.0 78 0.0 0.0 0.0 
41 74.2 41.2 57.6 79 0.4 0.0 0.2 
42 69.6 36.3 52.9 80 0.0 0.0 0.0 
43 67.6 35.8 51.7 81 0.0 0.0 0.0 
44 64.1 35.2 49.6 82 0.4 0.0 0.2 
45 62.6 33.7 48.1 83 0.0 0.0 0.0 
46 62.6 34.3 48.4 84 0.0 0.0 0.0 
47 61.1 33.9 47.4 85 0.0 0.0 0.0 
48 57.9 32.0 44.9 86 0.0 0.0 0.0 
49 57.6 28.6 43.0 87 0.0 0.0 0.0 
50 55.0 29.3 42.1 88 0.0 0.0 0.0 
51 56.6 28.3 42.4 89 1.2 0.0 0.4 
52 50.6 27.2 38.8 90 0.0 0.0 0.0 
Notes 
1. Only unit record data from WA, SA, Tas, NT and ACT were used to produce this table. Vic and Qld data were 
not available; NSW data were excluded due to incomplete coverage. 
2. Australian population estimates for June 2013 were used to produce this table (ABS 2014a).  
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Table A7: Clients receiving pharmacotherapy on a snapshot 
day, by age group and sex, 2013  
  Male Female All clients 
Age group 
(years) % 
15–19 0.1 0.1 0.1 
20–24 2.3 2.4 2.3 
25–29 7.4 8.9 7.9 
30–34 16.5 18.1 17.1 
35–39 18.2 18.1 18.2 
40–44 17.8 17.7 17.8 
45–49 14.2 14.3 14.2 
50–54 12.5 12.0 12.4 
55–59 7.9 6.6 7.4 
60–64 2.7 1.5 2.3 
65–69 0.3 0.2 0.3 
70–74 0.1 0.1 0.1 
75 and over 0.0 0.0 0.0 
Total 100.0 100.0 100.0 
Note: Unit record data were used to produce this figure. Records were available for 58% 
of total clients receiving pharmacotherapy on a snapshot day in 2013. Vic and Qld data 
were not available. 
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Table A8: Clients receiving pharmacotherapy on a snapshot day, by Indigenous status 
and age group, 2013  
 
Indigenous clients 
Non-Indigenous 
clients 
Not 
stated 
Not 
reported All clients 
Age group  
(years) Number % Number Number Number Number % 
15–19 9 0.4 16 0 5 30 0.1 
20–24 132 5.2 427 8 76 643 2.3 
25–29 356 13.9 1,522 25 257 2,160 7.9 
30–34 548 21.4 3,387 79 662 4,676 17.1 
35–39 510 20.0 3,542 194 725 4,971 18.2 
40–44 487 19.1 3,491 317 569 4,864 17.8 
45–49 278 10.9 2,837 395 381 3,891 14.2 
50–54 151 5.9 2,391 522 323 3,387 12.4 
55–59 64 2.5 1,309 440 222 2,035 7.4 
60–64 18 0.7 386 160 62 626 2.3 
65–69 2 0.1 56 19 3 80 0.3 
70–74 1 0.0 11 4 1 17 0.1 
75 and over 0 0.0 7 1 0 8 0.0 
Total 2,556 100.0 19,382 2,164 3,286 27,388 100.0 
Notes 
1. Unit record data were used to produce this figure. Records were available for 58% of total clients receiving 
pharmacotherapy on a snapshot day in 2013 
2. The figure includes data from NSW, SA, Tas, the ACT and the NT. Qld data were not available; Vic and WA do not report 
Indigenous status. 
Table A9: Opioid drugs of dependence reported for clients receiving pharmacotherapy on a 
snapshot day, by state and territory, 2013  
Opioid drug of 
dependence NSW Vic Qld WA SA Tas ACT NT Australia Australia (%) 
Heroin 2,614 7,177 3,572 1,715 1,972 23 348 13 17,434 36.6 
Morphine 93 372 776 201 495 110 17 72 2,136 4.5 
Methadone 117 1,244 521 119 84 57 38 6 2,186 4.6 
Buprenorphine 144 648 281 108 149 10 4 2 1,346 2.8 
Codeine 171 246 299 104 192 20 6 0 1,038 2.2 
Oxycodone 571 496 405 100 254 43 1 0 1,870 3.9 
Other 
pharmaceutical 
opioids 29 52 38 26 33 0 14 27 219 0.5 
Not stated/not 
reported(a) 15,458 3,860 201 913 0 396 492 27 21,347 44.9 
Total(b) 19,197 14,095 6,093 3,286 3,179 659 920 147 47,576 100.0 
(a) ‘Not stated/not reported’ also includes ‘Inadequately described’ responses. 
(b) Clients can have up to 5 opioid drugs of dependence recorded. NSW, Qld, SA, Tas, the ACT and the NT reported 1 opioid drug of 
dependence per client. Vic reported multiple opioid drugs of dependence for a maximum of 1% of clients—these data have been 
included without amendment. WA reported multiple drugs of dependence for a maximum of 15% of clients—these data have been 
adjusted to allow comparisons between jurisdictions. Values for WA clients with multiple opioid drugs of dependence were imputed 
based on proportions reported for other WA clients. 
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Table A10: Clients receiving pharmacotherapy on a snapshot day, by client status, and 
state and territory, 2013  
Client status Vic Qld WA Tas Total Total (%) 
New 714 349 39 9 1,111 4.6 
Readmission 1,180 1,647 151 3 2,981 12.4 
Interstate transfer 8 — — — 8 0.0 
Ongoing 11,933 4,097 3,096 647 19,773 82.4 
Not stated 126 — — — 126 0.5 
Total  13,961 6,093 3,286 659 23,999 100.0 
Note: Data were not available for NSW, SA, ACT and NT. 
  
 54 National opioid pharmacotherapy statistics 2013 
Table A11: Prescribers, by pharmacotherapy type, and state and territory, 2005–2013 
Pharmacotherapy drug type NSW Vic  Qld WA SA Tas ACT NT Australia 
Australia 
(%) 
  2013 
Methadone only 236 119 1 4 — 11 — — 371 18.3 
Buprenorphine only(a) 92 — — — — — — — 92 4.5 
Buprenorphine-naloxone only n.a. 18 2 — 100 — — — 120 5.9 
More than 1 drug type 308 684 180 94 72 26 66 12 1,442 71.2 
Total (number) 636 821 183 98 172 37 66 12 2,025 100.0 
Total (per cent) 31.4 40.5 9.0 4.8 8.5 1.8 3.3 0.6 100.0 . . 
 
2012 
Methadone only 223 119 4 7 — 8 — — 361 20.4 
Buprenorphine only(a) 70 — — — — — — — 70 4.0 
Buprenorphine-naloxone only n.a. — 2 — 93 — — — 95 5.4 
More than 1 drug type 300 566 126 88 73 25 56 8 1,242 70.2 
Total (number) 593 685 132 95 166 33 56 8 1,768 100.0 
Total (per cent) 33.5 38.7 7.5 5.4 9.4 1.9 3.2 0.5 100.0 . . 
 
2011 
Methadone only 214 122 — — — 10 — — 346 22.3 
Buprenorphine only(a) 58 — — — — 1 — — 59 3.8 
Buprenorphine-naloxone only n.a. — — — 13 3 — — 16 1.0 
More than 1 drug type 285 473 105 116 72 21 47 9 1,128 72.8 
Total (number) 557 595 105 116 85 35 47 9 1,549 100.0 
Total (per cent) 36.0 38.4 6.8 7.5 5.5 2.3 3.0 0.6 100.0 . . 
 
2010 
Methadone only 214 122 1 — — — — — 337 23.3 
Buprenorphine only(a) 34 — — — — — — — 34 2.3 
Buprenorphine-naloxone only n.a. — 1 — — — — — 1 0.1 
More than 1 drug type 266 444 103 108 77 30 39 10 1077 74.3 
Total (number) 514 566 105 108 77 30 39 10 1449 100.0 
Total (per cent) 35.5 39.1 7.2 7.5 5.3 2.1 2.7 0.7 100.0 . . 
 
2009 
Methadone only 228 122 4 — — 12 9 — 375 26.1 
Buprenorphine only(a) 58 — 1 — — — — — 59 4.1 
Buprenorphine-naloxone only n.a. — 1 — — — — — 1 0.1 
More than 1 drug type 242 420 115 92 73 23 27 8 1000 69.7 
Total (number) 528 542 121 92 73 35 36 8 1435 100.0 
Total (per cent) 36.8 37.8 8.4 6.4 5.1 2.4 2.5 0.6 100.0 . . 
(continued) 
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Table A11 (cont.): Prescribers, by pharmacotherapy type, and state and territory, 2005–2013 
Pharmacotherapy drug type NSW Vic  Qld WA SA Tas ACT NT Australia 
Australia 
(%) 
 
2008 
Methadone only 199 122 2 14 — 24 10 — 371 27.1 
Buprenorphine only(a) 39 — 1 — — 18 — — 58 4.2 
Buprenorphine-naloxone only n.a. — 1 — — 5 — — 6 0.4 
More than 1 drug type 257 383 107 69 74 5 26 13 934 68.2 
Total (number) 495 505 111 83 74 52 36 13 1369 100.0 
Total (per cent) 36.2 36.9 8.1 6.1 5.4 3.8 2.6 0.9 100.0 . . 
 
2007 
Methadone only 176 122 2 15 — 29 11 — 355 27.9 
Buprenorphine only(a) 30 — 5 1 — 18 — — 54 4.2 
Buprenorphine-naloxone only n.a. — — — — 5 — — 5 0.4 
More than 1 drug type 246 350 92 70 74 — 14 14 860 67.5 
Total (number) 452 472 99 86 74 52 25 14 1274 100.0 
Total (per cent) 35.5 37.0 7.8 6.8 5.8 4.1 2.0 1.1 100.0 . . 
 
2006(b) 
Methadone only 123 122 9 15 — — 13 — 282 23.6 
Buprenorphine only(a) 287 — 5 1 — — 12 — 305 25.6 
Buprenorphine-naloxone only n.a. — — — — — — — — — 
More than 1 drug type — 314 120 52 65 48 — 7 606 50.8 
Total (number) 410 436 134 68 65 48 25 7 1,193 100.0 
Total (per cent) 34.4 36.5 11.2 5.7 5.4 4.0 2.1 0.6 100.0 . . 
  
 
  
        
 
2005(b)(c) 
Methadone only 123 112 10 15 — 42 13 — 315 25.5 
Buprenorphine only(a) — — 1 1 — — — — 2 0.2 
Methadone and buprenorphine 293 316 114 56 73 39 15 11 917 74.3 
Total (number) 416 428 125 72 73 81 28 11 1,234 100.0 
Total (per cent) 33.7 34.7 10.1 5.8 5.9 6.6 2.3 0.9 100.0 . . 
Note: The states and territories have different guidelines and policies regarding training to prescribe the pharmacotherapy types for opioid 
dependence. Please contact their respective health departments for specific information. 
(a) NSW counts buprenorphine-naloxone as ‘buprenorphine’. See Chapter 5 for further details. 
(b) Data on ‘buprenorphine-naloxone only’ prescribers were not reported in 2005 and 2006. However, in 2006, buprenorphine-naloxone was 
available for prescription but no instances of ‘buprenorphine-naloxone only’ prescribers were reported. 
(c) ‘Authorised to prescribe more than 1 drug type’ was not a valid response code in 2005. 
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Table A12: Clients receiving pharmacotherapy on a snapshot day, by 
pharmacotherapy type and prescriber type, 2005–2013 
Prescriber type Methadone Buprenorphine(a) 
Buprenorphine- 
naloxone 
All drug 
types 
 
2013 (number) 
Private prescriber 20,486 3,473 6,721 30,680 
Public prescriber 8,468 2,412 2,339 13,219 
Public/private prescriber(b) 209 69 — 278 
Correctional facility 2,828 214 223 3,265 
Total 31,991 6,168 9,283 47,442 
 
2013 (%) 
Private prescriber 64.0 56.3 72.4 64.7 
Public prescriber 26.5 39.1 25.2 27.9 
Public/private prescriber(b) 0.7 1.1 — 0.6 
Correctional facility 8.8 3.5 2.4 6.9 
Total 100.0 100.0 100.0 100.0 
  2012 (%) 
Private prescriber 64.5 57.2 74.1 65.3 
Public prescriber 26.4 38.4 23.9 27.6 
Public/private prescriber(b) 0.6 1.3 — 0.6 
Correctional facility 8.5 3.1 2.0 6.6 
Total 100.0 100.0 100.0 100.0 
  2011 (%) 
Private prescriber 63.4 57.7 75.7 64.8 
Public prescriber 26.6 37.9 22.3 27.4 
Public/private prescriber(b) 0.6 1.2 0.0 0.6 
Correctional facility 9.4 3.2 2.0 7.2 
Total 100.0 100.0 100.0 100.0 
 
2010 (%) 
Private prescriber 61.7 58.4 75.2 63.51 
Public prescriber 27.1 37.0 22.2 27.6 
Public/private prescriber(b) 1.0 1.9 — 0.9 
Correctional facility 10.3 2.7 2.6 7.9 
Total  100.0 100.0 100.0 100.0 
  2009 (%) 
Private prescriber 61.7 60.6 77.3 64.1 
Public prescriber 27.2 33.9 20.1 26.9 
Public/private prescriber(b) 1.1 2.0 — 1.0 
Correctional facility 10.1 3.5 2.7 8.0 
Total 100.0 100.0 100.0 100.0 
(continued) 
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Table A12 (cont.): Clients receiving pharmacotherapy on a snapshot day, by 
pharmacotherapy type and prescriber type, 2005–2013 
Prescriber type Methadone Buprenorphine(a) 
Buprenorphine- 
naloxone 
All drug 
types 
 
2008 (%) 
Private prescriber 62.8 63.6 76.1 65.0 
Public prescriber 27.3 31.7 20.4 26.9 
Public/private prescriber(b) 1.2 1.8 — 1.1 
Correctional facility 8.7 2.9 3.5 7.0 
Total 100.0 100.0 100.0 100.0 
 
2007 (%) 
Private prescriber 61.4 59.6 86.1 63.6 
Public prescriber 27.8 36.2 10.0 27.5 
Public/private prescriber(b) 1.3 1.2 — 1.2 
Correctional facility 9.5 3.0 3.9 7.7 
Total 100.0 100.0 100.0 100.0 
 
2006 (%) 
Private prescriber 61.9 65.2 91.3 64.2 
Public prescriber 28.3 30.1 8.2 27.7 
Public/private prescriber(b) 1.4 1.0 — 1.2 
Correctional facility 8.4 3.7 0.5 6.9 
Total 100.0 100.0 100.0 100.0 
 
2005 (%) 
Private prescriber 68.7 75.9 n.a. 69.8 
Public prescriber 23.3 20.9 n.a. 23.5 
Public/private prescriber(b) 0.2 0.1 n.a. 0.1 
Correctional facility 7.8 3.0 n.a. 6.6 
Total 100.0 99.9 n.a. 100.0 
(a) NSW counts buprenorphine-naloxone as ‘buprenorphine’. See Table 5.2 for further details. 
(b) These figures relate to prescribing that cannot be separated into public or private prescribers. 
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Table A13: Clients receiving pharmacotherapy on a snapshot day, prescribers and dosing point 
sites, by state and territory, 2005–2013 
  NSW Vic Qld WA SA Tas ACT NT Australia 
 
2013 
 
Number 
Total number of clients 19,197 13,961 6,093 3,286 3,179 659 920 147 47,442 
Total number of prescribers 636 821 183 98 172 37 66 12 2,025 
Total number of dosing points 804 482 511 246 205 62 34 11 2,355 
 
Ratio 
Ratio of clients to prescriber 30.2 17.0 33.3 33.5 18.5 17.8 13.9 12.3 23.4 
Ratio of clients to dosing point 23.9 29.0 11.9 13.4 15.5 10.6 27.1 13.4 20.1 
 
2012 
 
Number 
Total number of clients 18,715 14,035 5,819 3,273 3,215 626 893 121 46,697 
Total number of prescribers 593 685 132 95 166 33 56 8 1,768 
Total number of dosing points 764 458 470 237 199 55 33 10 2,226 
 
Ratio 
Ratio of clients to prescriber 31.6 20.5 44.1 34.5 19.4 19.0 15.9 15.1 26.4 
Ratio of clients to dosing point 24.5 30.6 12.4 13.8 16.2 11.4 27.1 12.1 21.0 
  2011 
 
Number 
Total number of clients 18,831 13,755 5,702 3,382 3,183 645 825 123 46,446 
Total number of prescribers 557  595 105 116 85 35 47 9 1,549 
Total number of dosing points 749 457 435 258 203 55 32 11 2,200 
 
Ratio 
Ratio of clients to prescriber 33.8 23.1 54.3 29.2 37.4 18.4 17.6 13.7 30.0 
Ratio of clients to dosing point 25.1 30.1 13.1 13.1 15.7 11.7 25.8 11.2 21.1 
 
2010 
 
Number 
Total number of clients 19,114 13,185 5,688 3,342 3,210 620 811 108 46,078 
Total number of prescribers 514 566 105 108 77 30 39 10 1,449 
Total number of dosing points 732 452 479 242 197 55 31 12 2,200 
 
Ratio 
Ratio of clients to prescriber 37.2 23.3 54.2 30.9 41.7 20.7 20.8 10.8 31.8 
Ratio of clients to dosing point 26.1 29.2 11.9 13.8 16.3 11.3 26.2 9.0 20.9 
 
2009 
 
Number 
Total number of clients 17,868 12,576 5,116 3,187 3,151 634 792 121 43,445 
Total number of prescribers 528 542 121 92 73 35 36 8 1,435 
Total number of dosing points 709 436 474 247 198 54 28 11 2,157 
 
Ratio 
Ratio of clients to prescriber 33.8 23.2 42.3 34.6 43.2 18.1 22.0 15.1 30.3 
Ratio of clients to dosing point 25.2 28.8 10.8 12.9 15.9 11.7 28.3 11.0 20.1 
 
2008 
 
Number 
Total number of clients 17,168 11,821 4,899 2,908 3,052 588 786 125 41,347 
Total number of prescribers 495 505 111 83 74 52 36 13 1,369 
Total number of dosing points 698 431 470 247 203 50 29 15 2,143 
 
Ratio 
Ratio of clients to prescriber 34.7 23.4 44.1 35.0 41.2 11.3 21.8 9.6 30.2 
Ratio of clients to dosing point 24.6 27.4 10.4 11.8 15.0 11.8 27.1 8.3 19.3 
(continued) 
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Table A13 (cont.): Clients receiving pharmacotherapy on a snapshot day, prescribers and dosing 
point sites, by state and territory, 2005–2013 
  NSW Vic Qld WA SA Tas ACT NT Australi
 
 
2007 
 
Number 
Total number of clients 16,348 11,051 4,30
 
2,82
 
2,834 600 765 114 38,843 
Total number of prescribers 452 472 99 86 74 52 25 14 1,274 
Total number of dosing points 680 425 484 242 215 49 28 12 2,135 
 
Ratio 
Ratio of clients to prescriber 36.2 23.4 43.5 32.8 38.3 11.5 30.6 8.1 30.5 
Ratio of clients to dosing point 24.0 26.0 8.9 11.7 13.2 12.2 27.3 9.5 18.2 
 
2006 
 
Number 
Total number of clients 16,355 10,736 4,63
 
2,88
 
2,823 602 790 134 38,965 
Total number of prescribers 410 436 134 68 65 48 25 7 1,193 
Total number of dosing points 660 413 503 244 175 48 28 10 2,081 
 
Ratio 
Ratio of clients to prescriber 39.9 24.6 34.6 42.5 43.4 12.5 31.6 19.1 32.7 
Ratio of clients to dosing point 24.8 26.0 9.2 11.8 16.1 12.5 28.2 13.4 18.7 
 
2005 
 
Number 
Total number of clients 16,469 10,753 4,44
 
2,88
 
2,857 588 764 183 38,937 
Total number of prescribers 416 428 125 72 73 81 28 11 1,234 
 
Ratio 
Ratio of clients to prescriber 39.6 25.1 35.5 40.0 39.1 7.3 27.3 16.6 31.6 
Notes 
1.  This table has been derived from tables A1, A11 and A16. 
2. From 2011 onward, South Australian data have been impacted by the introduction of the SOSP. This involved growth in the number of 
prescribers treating relatively few clients. On a snapshot day in 2013, for example, 100 prescribers registered under the SOSP (out of 172 
prescribers in total) treated a total of 150 clients. 
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Table A14: Ratio of clients to prescriber, by prescriber type, and state and territory, 2013 
Prescriber type NSW(a) Vic  Qld WA SA Tas ACT NT Australia 
Public prescriber 40.6 — 60.2 66.1 94.0 28.9 105.6 16.5 49.0 
Private prescriber 25.0 16.3 22.8 26.7 11.6 13.4 5.3 5.5 18.6 
Public/private prescriber 9.9 — 0.0(b) — — — 0.0(b) — 7.9 
Correctional facility 110.7 48.2 6.8 21.5 44.2 1.5 87.0 2.0 48.7 
Total 30.2 17.0 33.3 33.5 18.5 17.8 13.9 12.3 23.4 
(a) NSW has 8 prescribers who prescribe in more than 1 location, and as such are counted twice. This will lead to slightly 
deflated client to prescriber ratios.  
(b) For public/private prescribers in Qld and ACT, the number of clients receiving treatment is either zero or cannot be reported 
in this collection. 
Notes 
1. This ratio was calculated using the formula: number of clients by all pharmacotherapy types, prescriber type and 
state/territory (Table 3.3) divided by registered prescribers by prescriber type and state/territory (Table 3.2). 
2. See Table 5.2 for more information about reporting of registered prescribers. 
Table A15: Clients receiving pharmacotherapy treatment on a snapshot day, by prescriber 
type, sex and age group, 2013  
  
Public     
prescriber 
Private 
prescriber 
Public/private 
prescriber 
Correctional 
facility 
All     
prescribers 
 
Number % Number % Number % Number % Number % 
Sex 
 Male 6,021 61.9 9,539 63.4 166 59.7 2,068 88.3 17,794 65.0 
Female 3,707 38.1 5,500 36.6 112 40.3 275 11.7 9,594 35.0 
All clients 9,728 100.0 15,039 100.0 278 100.0 2,343 100.0 27,388 100.0 
           
Age group (years) 
Under 30 991 10.2 1,293 8.6 13 4.7 536 22.9 2,833 10.3 
30–39 3,524 36.2 4,986 33.2 79 28.4 1,058 45.2 9,647 35.2 
40–49 3,129 32.2 4,931 32.8 92 33.1 603 25.7 8,755 32.0 
50 and over 2,084 21.4 3,829 25.5 94 33.8 146 6.2 6,153 22.5 
Total 9,728 100.0 15,039 100.0 278 100.0 2,343 100.0 27,388 100.0 
Notes 
1. Unit record data were used to produce this table. Records were available for 58% of total clients receiving pharmacotherapy on 
a snapshot day in 2013. Vic and Qld data were not available. 
2. See Chapter 5 for more information about reporting of registered prescribers.
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Table A16: Dosing point sites, by state and territory, 2005–06 to 2012–13 
Dosing point sites NSW(a) Vic Qld WA SA Tas ACT NT Australia 
Australia 
(%) 
  2012–2013 
Public clinic 36 — 11 1 2 2 1 2 55 2.3 
Private clinic 12 — 7 — — — — — 19 0.8 
Pharmacy 680 455 411 241 193 58 32 8 2,078 88.2 
Correctional facility 1 11 5 2 8 1 1 1 30 1.3 
Other(b) 75 16 77 2 2 1 — — 173 7.3 
Total (number) 804 482 511 246 205 62 34 11 2,355 100.0 
Total (per cent) 34.1 20.5 21.7 10.4 8.7 2.6 1.4 0.5 100.0 . . 
  2011–2012 
Public clinic 36 — 10 1 2 1 1 1 52 2.3 
Private clinic 12 — 8 — — — — — 20 0.9 
Pharmacy 640 436 377 230 188 52 31 8 1,962 88.1 
Correctional facility 1 11 4 2 7 1 1 1 28 1.3 
Other(b) 75 11 71 4 2 1 — — 164 7.4 
Total (number) 764 458 470 237 199 55 33 10 2,226 100.0 
Total (per cent) 34.3 20.6 21.1 10.6 8.9 2.5 1.5 0.4 100.0 . . 
 
2010–2011 
Public clinic 37 — 11 1 2 1 1 3 56 2.5 
Private clinic 17 — — — — — — — 17 0.8 
Pharmacy 618 429 357 249 190 52 30 7 1,932 87.8 
Correctional facility 2 11 4 2 8 1 1 1 30 1.4 
Other(b) 75 17 63 6 3 1 — — 165 7.5 
Total (number) 749 457 435 258 203 55 32 11 2,200 100.0 
Total (per cent) 34.0 20.8 19.8 11.7 9.2 2.5 1.5 0.5 100.0 . . 
 
2009–2010 
Public clinic 37 — 10 1 2 1 1 3 55 2.5 
Private clinic 12 3 — — — — — — 15 0.7 
Pharmacy 601 421 355 234 184 53 29 7 1,884 85.6 
Correctional facility 1 10 11 2 8 1 1 2 36 1.6 
Other(b) 81 18 103 5 3 — — — 210 9.5 
Total (number) 732 452 479 242 197 55 31 12 2,200 100.0 
Total (per cent) 33.3 20.5 21.8 11.0 9.0 2.5 1.4 0.5 100.0 . . 
  2008–2009 
Public clinic 37 — 10 1 2 1 1 2 54 2.5 
Private clinic 12 3 — — — — — — 15 0.7 
Pharmacy 572 407 354 235 185 52 26 7 1,838 85.2 
Correctional facility 1 10 12 2 9 1 1 2 38 1.8 
Other(b) 87 16 98 9 2 — — — 212 9.8 
Total (number) 709 436 474 247 198 54 28 11 2,157 100.0 
Total (per cent) 32.9 20.2 22.0 11.5 9.2 2.5 1.3 0.5 100.0 . . 
(continued) 
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Table A16 (cont.): Dosing point sites, by state and territory, 2005–06 to 2012–13 
Dosing point sites NSW(a) Vic Qld WA SA Tas ACT NT Australia 
Australia 
(%) 
 
2007–2008 
Public clinic 37 — 10 1 2 1 1 3 55 2.6 
Private clinic 12 3 — — — — — — 15 0.7 
Pharmacy 558 403 353 233 189 48 26 10 1,820 84.9 
Correctional facility 2 10 16 2 10 1 2 2 45 2.1 
Other(b) 89 15 91 11 2 — — — 208 9.7 
Total (number) 698 431 470 247 203 50 29 15 2,143 100.0 
Total (per cent) 32.6 20.1 21.9 11.5 9.5 2.3 1.4 0.7 100.0 . . 
 2006–2007 
Public clinic 37 — 12 1 2 1 1 2 56 2.6 
Private clinic 12 3 — — — — — — 15 0.7 
Pharmacy 547 395 366 239 202 47 25 8 1,829 85.7 
Correctional facility 2 17 16 2 8 1 2 2 50 2.3 
Other(b) 82 10 90 — 3 — — — 185 8.7 
Total (number) 680 425 484 242 215 49 28 12 2,135 100.0 
Total (per cent) 31.9 19.9 22.7 11.3 10.1 2.3 1.3 0.6 100.0 . . 
 2005–2006 
Public clinic 36 — 14 1 2 1 1 1 56 2.7 
Private clinic 12 3 — — — — — — 15 0.7 
Pharmacy 533 385 378 241 164 46 25 7 1,779 85.5 
Correctional facility 1 10 20 2 6 1 2 2 44 2.1 
Other(b) 78 15 91 — 3 — — — 187 9.0 
Total (number) 660 413 503 244 175 48 28 10 2,081 100.0 
Total (per cent) 31.7 19.8 24.2 11.7 8.4 2.3 1.3 0.5 100.0 . . 
(a) See tables 5.1 and 5.2 for more information about NSW. 
(b) The category ‘Other’ includes hospital inpatient and outpatients, mobile dosing sites, non-government organisations, doctors’ surgeries 
and dosing points ‘not stated’. 
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Table A17: Clients receiving pharmacotherapy on a snapshot day, by pharmacotherapy type, 
dosing point site, and state and territory, 2013 
Dosing point 
 
NSW Vic Qld WA SA Tas ACT NT Total 
 
Methadone 
Public clinic 2,222 — 51 9 38 7 131 1 2,459 
Private clinic 2,233 — 314 — — — — — 2,547 
Pharmacy 7,579 8397 2,297 1,823 1,528 367 511 44 22,546 
Other(a) 2522 837 135 295 138 1 87 — 4015 
Not stated(b) — — 259 — 165 — — — 424 
Total 14,556 9,234 3,056 2,127 1,869 375 729 45 31,991 
 
Buprenorphine(c) 
Public clinic 971 — 2 1 — 9 6 — 989 
Private clinic 808 — 102 — — — — — 910 
Pharmacy 2,193 524 459 106 43 44 24 18 3,411 
Other(a) 669 7 26 — — 2 — — 704 
Not stated(b) — — 119 — 35 — — — 154 
Total 4,641 531 708 107 78 55 30 18 6,168 
 
Buprenorphine-naloxone 
Public clinic n.a. — 35 2 32 36 46 5 156 
Private clinic n.a. — 235 — — — — — 235 
Pharmacy n.a. 4,116 1,310 1,018 1,005 183 115 75 7,822 
Other(a) n.a. 80 136 32 99 10 — 4 361 
Not stated(b) n.a. — 613 — 96 — — — 709 
Total n.a. 4,196 2,329 1,052 1,232 229 161 84 9,283 
 
Total (all pharmacotherapy drugs) 
Public clinic 3,193 — 88 12 70 52 183 6 3,604 
Private clinic 3,041 — 651 — — — — — 3,692 
Pharmacy 9,772 13,037 4,066 2,947 2,576 594 650 137 33,779 
Other(a) 3191 924 297 327 237 13 87 4 5080 
Not stated(b) — — 991 — 296 — — — 1,287 
Total (number) 19,197 13,961 6,093 3,286 3,179 659 920 147 47,442 
 
Total (per cent all pharmacotherapy drugs) 
Public clinic 16.6 — 1.4 0.4 2.2 7.9 19.9 4.1 7.6 
Private clinic 15.8 0.0 10.684 0.0 — — — — 7.8 
Pharmacy 50.9 93.4 66.7 89.7 81.0 90.1 70.7 93.2 71.2 
Other(a) 16.6 6.6 4.9 10.0 7.5 2.0 9.5 2.7 10.7 
Not stated(b) — — 16.3 0.0 9.3 — — — 2.7 
Total (per cent) 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
(a) The category ‘Other’ includes hospitals, mobile dosing sites, community health clinics, non-government organisations, doctors’ 
surgeries and dosing points ‘not stated’. 
(b) In Qld, the category ‘Not stated’ refers to clients who received their pharmacotherapy drug at a dosing point before the 
‘snapshot/specified’ day, that is, they received a takeaway dose. In SA, ‘Not stated’ refers to clients registered to receive 
treatment but who failed to dose. 
(c) NSW counts buprenorphine-naloxone as ‘buprenorphine’. See Chapter 5 for further details. 
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Table A18: Clients receiving pharmacotherapy on a snapshot day, by pharmacotherapy 
type and dosing point site, 2006–2013 
Dosing point site Methadone Buprenorphine(a) Buprenorphine-
 
Total 
 
2013 (number) 
Public clinic 2459 989 156 3,604 
Private clinic 2547 910 235 3,692 
Pharmacy 22,546 3,411 7,822 33,779 
Correctional facility 2,842 232 240 3,314 
Hospital 339 82 63 484 
Other(b) 834 390 58 1282 
Not stated(c) 424 154 709 1287 
Total 31,991 6,168 9,283 47,442 
 
2013 (%) 
Public clinic 7.7 16.0 1.7 7.6 
Private clinic 8.0 14.8 2.5 7.8 
Pharmacy 70.5 55.3 84.3 71.2 
Correctional facility 8.9 3.8 2.6 7.0 
Hospital 1.1 1.3 0.7 1.0 
Other(b) 2.6 6.3 0.6 2.7 
Not stated(c) 1.3 2.5 7.6 2.7 
Total 100.0 100.0 100.0 100.0 
 
2012 (%) 
Public clinic 7.7 16.1 1.4 7.7 
Private clinic 8.2 15.3 1.8 8.0 
Pharmacy 70.5 52.3 86.2 70.9 
Correctional facility 8.7 3.2 1.9 6.7 
Hospital 1.2 1.6 0.7 1.2 
Other(b) 2.5 6.3 0.6 2.6 
Not stated(c) 1.3 5.2 7.5 3.0 
Total 100.0 100.0 100.0 100.0 
 2011 (%) 
Public clinic 8.3 15.9 2.1 8.3 
Private clinic 7.3 13.4 0.0 6.8 
Pharmacy 69.3 54.8 83.5 69.8 
Correctional facility 9.3 3.2 2.1 7.2 
Hospital 1.0 1.9 0.7 1.1 
Other(b) 2.3 4.9 0.4 2.3 
Not stated(c) 2.4 6.0 11.2 4.5 
Total 100.0 100.0 100.0 100.0 
(continued) 
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Table A18 (cont.): Clients receiving pharmacotherapy on a snapshot day, by 
pharmacotherapy type and dosing point site, 2006–2013 
Dosing point site Methadone Buprenorphine(a) Buprenorphine-
 
Total 
 2010 (%) 
Public clinic 9.1 18.3 2.4 9.2 
Private clinic 7.8 14.7 0.2 7.5 
Pharmacy 66.7 53.4 83.0 67.6 
Correctional facility 10.2 2.8 2.3 7.9 
Other(b) 3.7 6.4 1.0 3.6 
Not stated(c) 2.6 4.5 11.1 4.3 
Total 100.0 100.0 100.0 100.0 
 
2009 (%) 
Public clinic 9.5 16.5 2.8 9.4 
Private clinic 8.0 13.0 0.2 7.4 
Pharmacy 68.1 56.9 83.6 69.1 
Correctional facility 9.8 3.2 2.4 7.7 
Other(b) 4.6 10.4 11.1 6.4 
Total 100.0 100.0 100.0 100.0 
  2008 (%) 
Public clinic 10.7 14.9 2.9 10.1 
Private clinic 8.4 12.7 0.2 7.7 
Pharmacy 67.6 59.8 86.9 69.4 
Correctional facility 8.8 2.9 3.0 7.1 
Other(b) 4.5 9.7 7.0 5.7 
Total 100.0 100.0 100.0 100.0 
 
2007 (%) 
Public clinic 11.9 14.2 2.2 10.8 
Private clinic 8.9 9.8 0.7 8.8 
Pharmacy 67.1 69.6 93.0 68.9 
Correctional facility 9.3 2.7 4.1 8.9 
Other(b) 2.8 3.7 — 2.7 
Total 100.0 100.0 100.0 100.0 
 
2006 (%)(d) 
Public clinic 12.9 12.7 1.5 12.3 
Private clinic 9.3 8.5 1.8 8.7 
Pharmacy 67.4 73.9 94.5 70.4 
Correctional facility 8.5 3.5 2.2 7.0 
Other(b) 1.9 1.5 — 1.7 
Total 100.0 100.0 100.0 100.0 
(a) NSW counts buprenorphine-naloxone as ‘buprenorphine’. See Chapter 5 for further details. 
(b) The category ‘Other’ includes mobile dosing sites, non-government organisations, doctors’ surgeries and dosing points ‘not 
stated’. From 2009 and earlier ‘Other’ also includes ‘not reported’. From 2010 onward, ‘not stated’ became a separate 
category. 
(c) In Qld, the category ‘Not stated’ refers to clients who received their pharmacotherapy drug at a dosing point before the 
‘snapshot/specified’ day—that is, they received a takeaway dose. In SA, ‘Not stated’ refers to clients registered to receive 
treatment but who failed to dose. 
(d) The total estimated number of clients reported in 2006 excludes pharmacotherapy clients in the NT as data relating to 
dosing point sites and clients were not available.  
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Table A19: Clients receiving pharmacotherapy on a snapshot day, by dosing point type, sex and age group, 2013  
  Public clinic Private clinic Pharmacy 
Correctional 
facility Hospital Other Not stated 
All dosing 
points 
 Number % Number % Number % Number % Number % Number % Number % Number % 
Age group (years)                
Under 30 438 12.7 421 13.8 1,035 7.3 513 23.8 36 12.9 90 7.6 300 9.4 2,833 10.3 
30–39 1,274 37.0 1,111 36.5 4,728 33.5 988 45.8 107 38.4 393 33.1 1,046 32.9 9,647 35.2 
40–49 1,086 31.5 885 29.1 4,631 32.8 525 24.4 86 30.8 421 35.5 1,121 35.3 8,755 32.0 
50 and over 648 18.8 624 20.5 3,706 26.3 130 6.0 50 17.9 283 23.8 712 22.4 6,153 22.5 
  Sex                 
Male 2,191 63.6 2,190 72.0 8,597 61.0 1,882 87.3 161 57.7 721 60.7 2,052 64.5 17,794 65.0 
Female 1,255 36.4 851 28.0 5,503 39.0 274 12.7 118 42.3 466 39.3 1,127 35.5 9,594 35.0 
                 
Total 3,446 100.0 3,041 100.0 14,100 100.0 2,156 100.0 279 100.0 1,187 100.0 3,179 100.0 27,388 100.0 
Note: Unit record data were used to produce this figure. Records were available for 58% of total clients receiving pharmacotherapy on a snapshot day in 2013. Vic and Qld data were not available. 
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Appendix B: NOPSAD 2013 Data quality 
statement 
Summary of key data quality issues 
• Each state and territory uses a slightly different method to collect data about the 
pharmacotherapy used to treat those with opioid dependence. These differences are 
driven by differences between the states and territories in relation to legislation, 
information technology systems and resources. The differences may result in 
discrepancies when comparing one state or territory with another. 
• New South Wales is unable to differentiate between clients prescribed buprenorphine 
and buprenorphine-naloxone. 
• Victoria and Western Australia do not provide data in relation to the Indigenous status 
of clients. 
• In Western Australia, the number of clients receiving pharmacotherapy treatment is 
reported through the month of June (rather than on a snapshot day), likely resulting in 
higher numbers reported by WA than by other jurisdictions. 
• In 2013, Victoria was unable to provide reliable age and sex data for individual 
pharmacotherapy drug types. This is different to previous years, where an imputation 
strategy was used. Footnotes have been made to affected figures and tables to highlight 
this change.  
• Analyses of 2 new data items (opioid drugs of dependence and client status) have been 
included. Both items contain gaps in data coverage. These gaps have been noted in 
footnotes and body text relating to each new data item. 
• This 2013 NOPSAD report includes unit record analyses for the first time. Unit record 
data were provided by 6 out of 8 jurisdictions (comprising 58% of total clients). Selected 
data elements were not provided by all 6 jurisdictions (for example, Indigenous status). 
For figures and tables based on unit record data, footnotes and explanations in body text 
have been included to highlight gaps in data coverage. 
Description 
The NOPSAD collection includes information on 3 opioid pharmacotherapy drugs used for 
treating opioid dependence. These drugs are methadone, buprenorphine and 
buprenorphine-naloxone (Box 1.2). Each state and territory collects agreed data about clients 
receiving opioid pharmacotherapy on a snapshot day, usually in June each year. The 
snapshot day varies between states and territories. See Table 5.1 for information about the 
use of the snapshot day for each state and territory. 
Since 2012, selected jurisdictions have provided the AIHW with unit record data in addition 
to aggregate data. Although unit record data are not yet provided by all jurisdictions, this 
2013 NOPSAD report is the first to include analyses based on unit record data (provided by 
New South Wales, Western Australia, South Australia, Tasmania, the Northern Territory and 
the Australian Capital Territory).  
While states and territories strive to report data consistent with agreed standards, the 
NOPSAD collection is not a national minimum data set and some discrepancies exist 
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between the ways in which data are reported. These discrepancies are discussed in more 
detail in Chapter 5. 
The NOPSAD collection is one of a number of data sources that provide a picture of alcohol 
and other drug treatment services in Australia. 
Institutional environment  
The AIHW is a major national agency set up by the Australian Government under the 
Australian Institute of Health and Welfare Act 1987 to provide reliable, regular and relevant 
information and statistics on Australia’s health and welfare. It is an independent statutory 
authority established in 1987, governed by a management board, and accountable to the 
Australian Parliament through the Health portfolio. 
The AIHW aims to improve the health and wellbeing of Australians through better health 
and welfare information and statistics. It collects and reports information on a wide range of 
topics and issues, ranging from health and welfare expenditure, hospitals, disease and 
injury, and mental health, to ageing, homelessness, disability and child protection. 
The Institute also plays a role in developing and maintaining national metadata standards. 
This work contributes to improving the quality and consistency of national health and 
welfare statistics. The Institute works closely with government and non-government 
organisations to achieve greater adherence to these standards in administrative data 
collections to promote national consistency and comparability of data and reporting. 
One of the main functions of the AIHW is to work with the states and territories to improve 
the quality of administrative data and, where possible, to compile national data sets based on 
data from each jurisdiction, to analyse these data sets and disseminate information and 
statistics. 
The Australian Institute of Health and Welfare Act 1987, in conjunction with compliance to the 
Privacy Act 1988 (Cth), ensures that the data collections managed by the AIHW are kept 
securely and under the strictest conditions with respect to privacy and confidentiality. 
For further information see the AIHW website <www.aihw.gov.au>. 
Timeliness 
Data are collected by states and territories on a snapshot day, usually in June. Jurisdictions 
receive, collate and clean this data, providing it in aggregate form to the AIHW between 
October and December each year. The AIHW analyses and reports on the data provided, 
with annual data available 6 months after the finalisation of the national data set, usually in 
June. 
Accessibility 
Results from the collection are published in an annual report that can be accessed via the 
AIHW website. An accompanying data guide is also produced annually. This data guide 
outlines the data elements to be collected in more detail. Additional data requests can also be 
made on an ad hoc basis. 
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Interpretability 
Information on opioid use is available in the AIHW annual report. Definitions of terms used 
are in the report to assist with interpretability. 
Relevance 
The NOPSAD collection is essential in monitoring treatment for opioid dependence 
nationally. It is one of a number of data sources that provide a picture of alcohol and other 
drug treatment services in Australia. Data from the collection can also be considered with 
information from other sources—for instance, the Alcohol and Other Drug Treatment 
Services National Minimum Data Set (AODTS NMDS) and the National Drug Strategy 
Household Survey (NDSHS)—to inform debate, policy decisions and planning processes 
that occur within the broader alcohol and other drug treatment sector. More specifically, 
pharmacotherapy data are used in states and territories to: 
• monitor resources required for pharmacotherapy treatment, such as the number of 
prescribers and dosing point sites 
• monitor and plan services (for example, monitoring prescriber patterns and the number 
of clients) 
• develop and refine policies relating to the treatment of clients with opioid dependency 
• track the number of clients moving between the public and private sectors. 
Data are also used more broadly to fill gaps in national treatment services data. 
Accuracy 
NOPSAD data are collected on a snapshot day, usually in June each year. This method is 
appropriate for the collection and should be kept in mind when comparing the NOPSAD 
collection with other collections that use different data collection periods.  
Due to variations between states and territories in data collection methods and some 
NOPSAD elements, discrepancies noted in Chapter 5 should be kept in mind when 
interpreting these data. 
Coherence 
The NOPSAD collection is reported annually. The method of data collection and elements 
collected is consistent between years, allowing for meaningful comparisons over time. 
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Appendix C: Data requests and related 
data collections 
Data requests 
The states and territories are the data custodians of information collected through the 
NOPSAD collection in their state or territory. The AIHW is the data custodian of collated 
national information obtained from each state and territory. For the AIHW, data 
custodianship means responsibility for protection, storage, analysis and dissemination of the 
data in accordance with the purpose for which the data were collected, the Australian 
Institute of Health and Welfare Act 1987, other legislation and relevant privacy principles. 
Data requests to the AIHW can be made for summarised aggregate tables. Unit record data 
for 2012 and 2013 may be available for some jurisdictions on request.  
Additional information about the collection can be found in the NOPSAD 2013 data guide, 
which is available by contacting the AIHW and on the AIHW website: 
<https://www.aihw.gov.au/national-opioid-pharmacotherapy-statistics-annual-data-
collection/>). 
Related data collections 
As in previous years, a subset of the data presented in this report will be in the forthcoming 
Alcohol and other drug treatment services in Australia 2012–13 report, due for release in 
mid-2014. 
If the data you require are not available from the NOPSAD collection, they may be available 
from the following sources: 
• Alcohol and Other Drug Treatment Services National Minimum Data Set  
Australian Institute of Health and Welfare 
<www.aihw.gov.au/alcohol-and-other-drugs-treatment-services-statistics>  
• The Health of Australia’s Prisoners 2012 
Australian Institute of Health and Welfare 
<https://www.aihw.gov.au/publication-detail/?id=60129543948> 
• National Drug Strategy Household Survey  
Australian Institute of Health and Welfare 
<www.aihw.gov.au/national-drugs-strategy-household-surveys>  
• Pharmaceutical Benefits Scheme 
Department of Health  
<www.pbs.gov.au/info/browse/statistics>. 
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